



I'm not robot



Continue

Aha guidelines 2018 cpr

1Top 10 Take-home Messages For Adult Cardiovascular Life Support On recognition of a cardiac arrest event, layperson simultaneously and immediately activates the emergency response system and initiates cardiopulmonary resuscitation (CPR). High-quality CPR performance includes adequate compression depth and rates while minimizing the pause in compression. Early defibrillation with simultaneous high-quality CPR is critical to survival when sudden cardiac arrest is caused by ventricle fibrillation or ventricle-free tachycardia. The administration of epinephrine with high-quality CPR simultaneously increases survival, especially in patients with inevitable rhythms. Recognition that all cardiac arrest events are not the same is critical for optimal patient outcomes, and specialized management is necessary for many conditions (for example, electrolyte abnormalities, pregnancy, after heart surgery). The opioid epidemic has led to an increase in out-of-hospital cardiac arrest associated with opioids, with permanent care mainstays activating high-quality CPR response systems and high-quality CPR performance. Post-heart capture care is a critical component of the Survival Chain and demands a comprehensive, organized, multi-disciplinary system that requires consistent execution for optimal patient outcomes. The immediate start of targeted temperature management is necessary for all patients who do not comply with the instructions after the return of spontaneous circulation to ensure optimal functional and neurological outcomes. Accurate neurological prognostics in brain-injured cardiac arrest victims are essential to ensure that patients with significant potential for rehabilitation are not destined for certain poor outcomes due to care production. Expectations of rehabilitation and survival plans addressing treatment, surveillance, and rehabilitation should be given to victims of cardiac arrest and their carers at hospital clearances to optimize the transition of care to home and outpatient environments. 2Preamble In 2015, about 350 000 adults in the United States suffered out-of-hospital cardiac arrest (OHCA) attended by emergency medical services staff (EMS).1 About 10.4% of patients with OHCA survived from their initial hospitalization, and 8.2% survived with good functional status. The main driver of successful resuscitation of the OHCA is the savour of cardiopulmonary resuscitation (CPR) and public use of automatic external defibrillator (AED). Despite recent gains, only 39.2% of adults received CPR initiated by layperson, and the public using AED in just 11.9% of survival rates from OHCA differ dramatically between us territory and the AGENCY EMS.2.3 After significant improvements, survival from OHCA was coated 2012. About 1.2% of U.S. hospitalized adults suffered cardiac arrest in hospital (IHCA).1 Of these patients, 25.8% were discharged from live hospitals, and 82% of the have a good functional status at the time of release. Despite a steady increase in survival rates from the IHCA, many opportunities remain. The Formula of the International Relations Committee on Resuscitation (ILCOR) for Survival emphasizes 3 important components for good resuscitation outcomes: guidelines based on sound resuscitation science, effective education of public providers and resuscitation, and the implementation of the Survival Chain.4 These Guidelines contain recommendations for basic life support (BLS) and advanced life support (ALS) for adult patients and based on the best resuscitation sciences. The Survival Chain, introduced in the Main Concept, is now expanded to emphasize the vital components of survivorship during rehabilitation from cardiac arrest, requiring coordinated efforts from medical professionals in various disciplines and, in the case of OHCA, from layer rescues, emergency dispatchers, and first responders. In addition, specific recommendations on resuscitation provider training are provided in Part 6: Educational Science Resuscitation, and recommendations on the care system are provided in Part 7: Care System. 3Introduction 3.1 Scope The Guidelines are designed primarily for North American healthcare providers who are looking for the latest summary for BLS and ALS for adults as well as for those seeking more in-depth information on resuscitation science and gaps in current knowledge. BLS teenage care follows adult guidelines. This Part of the American Heart Association (AHA) Guidelines 2020 for CPR and Emergency Cardiovascular Care include recommendations for clinical care of adults with cardiac arrest, including those with life-threatening conditions where cardiac arrest will occur, and after successful resuscitation from cardiac arrest. Some suggestions are directly

CPR devices convey automatic chest compression, thereby eliminating the need for manual chest compression. There are 2 different types of mechanical CPR devices: load distribution compression bands that compress the entire thorax circumference and pneumatic piston device that compresses the chest in the direction of anteroposterior. A recent systematic review of 11 RCTs (in total moderate to low certainty of evidence) found no evidence of better survival with good neurological outcomes with mechanical CPR compared to manual CPR either OHCA or IHCA.1 Given the perceived logistics advantages associated with limited staff and safety during patient transport, mechanically ACD-CPR is done using a portable device with a suction cup used on midsternum, actively lifting the chest during decompression, thereby increasing the negative intrathoracic pressures produced by the recoil chest and increasing the return of venous and heart output during the next chest compression. ITD is a sensitive pressure valve attached to advanced airways or face masks that limit air entry into the lungs during the CPR decompression phase, increasing the negative intrathoracic pressure produced during chest wall recoil and increases venous returns and heart output during CPR. There are many alternative CPR techniques used, and many are not proven. For example, there is insufficient evidence of cardiac arrest bonding with the entry of CPR heads-ups to provide recommendations on its use.2 Further investigation in this and other alternative CPR techniques best explored in the context of formal controlled clinical research proposals for Formal Mechanical CPR Devices COR LOE Proposition 2b-LD. The use of mechanical CPR devices can be considered in certain settings in which high-quality manual compression delivery may be challenging or dangerous for suppliers, as long as rescuers limit disruption in CPR during device usage and removal. 3: No Benefit B-R 2. Routine use of mechanical CPR devices is not recommended. Specific Support Text Suggestions and 2. Mechanical CPR device studies show no benefit when compared to manual CPR, with recommendations of more severe neurological outcomes in some studies. ASPIRE trial (1071 patients), use of load distributor band devices are associated with the same possibility of living for hospital clearance (adjusted odds ratio [aOR], 0.56; CI, 0.31–1.00; P=0.06), and worse survival with good neurological outcomes (aOR, 0.80; CI, 0.47–1.37).4 In paraMEDIC trials (n=4470), the use of mechanical piston devices produces the same 30-day survival rate (aOR, 0.86; CI, 0.64–1.15), and worse survival with good neurological outcomes (aOR, 0.72; CI, 0.52–0.99), compared with CPR.5 manual In LINC trials (n=2589), survival with good neurological outcomes was similar in both groups (8.3% compared to 7.8%; risk differences, 0.55%; 95% CI, -1.5% to 2.6%).6 Acknowledge this data, the use of mechanical CPR devices by trained personnel can be beneficial in settings where high-quality manual compression is unlikely or may cause risk to staff (i.e., limited staff, mobile ambulances, angiographic suites, prolonged resuscitation, or with concerns for the exposure of infectious diseases). This topic was last received an official evidence review in 2015.7 Proposal for Active Compression CPR And Impedance Threshold Device COR LOE Proposed 2b-BNR 1. The effectiveness of active compression-decompression CPR is uncertain. Active compression CPR may be considered for use when suppliers are adequately trained and monitored. 2b C-LD 2. The combination of active compression CPR and impedance threshold devices may be reasonable in settings with available equipment and trained personnel. 3: No Benefit A 3. Routine use of impedans threshold devices in addition to current conventional CPR is not recommended. Recommendations Text Support A 2013 Cochrane Review 10 attempt to compare ACD-CPR with standard CPR found no difference in the functioning of death and neurology in adults with OHCA or IHCA.8 Important additional considerations with this modality is that increased fatigue of the rescue, which can affect the overall quality of CPR. ACD-CPR and ITD can act synergistically to increase venous returns during chest decompression and increase blood flow to vital organs during CPR. ResQTrials points out that ACD plus ITD is associated with better survival for hospital emissions with encouraging neurological functions for OHCA compared to standard CPR, although this study is limited by blind shortages, different CPR feedback elements between the study weapons (i.e., counterintervention), lack of CPR quality assessment, and early TOR.9 CPR and Emergency Cardiovascular Care7 evaluate this topic and state that despite the large RCT its use, additional attempts are needed to verify results due to limitations of the study are mentioned. Therefore, ACD-CPR plus ITD is not recommended in previous versions of the AHA Guidelines. However, in settings where equipment and trained personnel are available, ACD-CPR and ITD can be an alternative to standard CPR. In the PRIMED study (n=8178), the use of ITD (as opposed to sham devices) did not significantly increase survival to hospital discharge or survival with good neurological function in patients with OHCA.11 Despite the addition of post-hoc analysis of PRIMED trials for ITD, 12 ID routine use in addition to this topic was last received an official evidence review in 2015.7 Recommendations for Alternative CPR Techniques COR LOE Recommendation 2b-BNR 1. CPR compression of the connected stomach can be considered during resuscitation in hospital when adequate staff trained in their use are available. Specific Recommendations Text Support Interposed stomach compression CPR is a 3-savior technique that includes conventional chest compression combined with intermittent stomach compression. Dedicated rescuers providing manual stomach compression will compress the stomach between xiphoids and umbilicus during the chest compression relaxation phase. The topic was last reviewed in 2010 and identified 2 random tests, a CPR compression abdominal interposed conducted by trained rescues increasing short-term survival of 0.13 and survival to hospital relief.14 compared to conventional CPR for adult IHCA. An adult RCT OHCA15 shows no live advantages for the abdominal interposed compression of CPR. More assessments are needed to determine the routine use of this technique. This topic was last received an official evidence review in 2010.16

6.3 Extracorporeal CPR Synopsis ECPR referred to the onset of cardiopulmonary bypass during patient resuscitation in cardiac arrest. This involves insulation of large veins and arteries and the beginning of extracorporeal venoarterial circulation and oxygenation membrane (ECMO) (Figure 8). The goal of the ECPR is to support final organ perfusion while potentially reversible conditions are addressed. The ECPR is a complex intervention that requires highly trained teams, specialized equipment, and multi-disciplinary support in the healthcare system. A 2019 update focused on ACLS1 guidelines addressing the use of ECPR for cardiac arrest and noting that there is insufficient evidence to recommend the use of ECPR routines in cardiac arrest. However, the ECPR could be considered if there is a potentially reversible cause of arrest that will benefit from temporary cardiorespiratory support. An important consideration is the selection of patients for the ECPR and further research is needed to determine the most will benefit from intervention. Furthermore, the intensity of the resources needed to start and maintain the ECPR program should be considered in the context of strengthening the link in Survival Chain. Additional investigations are necessary to assess the cost effectiveness, allocation of resources, and ethics surrounding the routine use of the ECPR in resuscitation. Recommendations of Text Support No RCTs use ECPR for OHCA or IHCA. Five observational studies have been identified for OHCA that vary in entry criteria, ECPR settings, and study design, with the majority of studies reporting better neurological outcomes associated with the use of ECPR.2 For ECPR in the hospital environment, all studies have been assessed as having a very serious bias risk (mainly due to confounding) and the overall certainty of evidence is rated as very low for all outcomes.2 In 3 studies, The ECPR is not associated with beneficial effects for short-term or long-term neurological outcomes, 3-5 while 1 study6 reports related to short-term and long-term although many studies reported good results with the use of the ECPR, the vast majority of studies were from single centers with various entry criteria and settings, with the decision to implement the ECPR made on a case-by-case basis. Although there is currently no evidence to clearly determine what should be selective patients, most of the analyzed studies include younger patients with less comorbidities. More clear data is needed from higher methodological quality studies, including randomized tests. The recommendation was supported by a 2019 update focusing on the guidelines of ACLS.1 7 Specific Arrhythmia Management 7.1 Wide-Komplex Tachycardia Proposal for High Complex Hemodynamic Pharmacology Management Tachycardia COR LOE Proposed 2b-BNRR 1. In stable hemodynamic patients, IV adenosine can be considered for treatment and helps diagnose rhythms when the cause of normal rhythm, monomorphic cannot be determined. 2b B-R 2. Administration of IV amiodarone, procainamide, or sotalol can be considered for the treatment of extensive tachycardia. 3: Harm B-NR 3. Verapamil cannot be administered for any vast complex tachycardia unless it is known to come from supraventricular and is not operated by an accessory pathway. 3: C-LD Harm 4. Adenosine should not be administered for unstable, unstable, irregular hemodial, or vast polymorphic complex tachycardias. The vast Synopsis of Tachycardia is defined as a rapid rhythm (generally 150 bran/min or more when associated with arrhythmias) with a QRS period of 0.12 seconds or more. It can represent any supraventricular tachycardia (SVT), including a paroxysmal SVT caused by re-entry of atrioventricular (AV), aberrantly fibrillation atrium, atrial flutter, or tachycardia atrium ectopic. Extensive tachycardia can also be caused by any of these supraventricular arrhythmias when operated by accessory routes pre-splended arrhythmias). Conversely, the extensive tachycardia can also be caused by VT or rapidly rapidly rhythm paced in patients with pacemaker. The initial management of complex tachycardia requires a rapid assessment of the patient's hemodynamic stability. Unstable patients need immediate electric cardioversion. If haemodynamics are stable, the diagnosis of presumptive rhythm should be tried by getting a 12-lead ECG to assess the characteristics of tachycardia. This includes identifying waves P and their relationship with the QRS complex and (in the case of patients with pacemaker) pacing spikes ahead of the vast QRS. Tachycardia complex can be common or irregular and have a uniform (monomorphic) or different (polymorphic) complex QRS from beat to beat. Each of these features can also be useful in making a diagnosis of presumptive rhythm. Inregated tachycardia with monomorphic QRS complex suggests atrial fibrillation with aflutter, while pre-excited atrial fibrillation or polymorphic VT may be when the QRS complex changes in their configuration from beat to beat. On the other hand, common wide-width complex tachycardia can represent monomorphic VT or aberrant-operated paroxysmal SVT, ectopic atrial tachycardia, or atrial flutter. Distinguishing between the etiology of this rhythm is the key to proper selection of drugs for treatment. Although stable haemorrhidy provides an opportunity for pharmacological assessment and treatment, the need for immediate electrical cardioversion should be expected if arrhythmias prove unresponsive to these measures or rapid commotion occurs. A more detailed approach to rhythm management is found elsewhere.1-3 Recommendations Text Support Before starting empirical drug therapy, getting ECG 12-lead and/or seeking specialist consultation for diagnosis is encouraged, if any. If the usual widespread tachycardia is suspected as a paroxysmal SVT, vagal maneuvers can be considered before starting pharmacological therapy (See Common Narrow Complex Tachycardia). Adenosine is an effective short ultra-acting drug in ending regular tachycardias when caused by an AV entry Adenosine usually will not end atrial arrhythmia (such as atrial flutter or atrial tachycardia) but will intentionally slow the ventricle rate by blocking the flow of waves P via AV nodes, capable of Although ineffective in ending ventricular arrhythmia, the relatively short life effect on blood pressure makes it less likely to weaken VT monomorphy in stable hemodynamic patients. These characteristics make adenosine relatively safe to treat stable, common hemodynamics, monomorphic width complex tachycardia of unknown types4 and as an aid in rhythmic diagnosis, although its consumption is not entirely without risk.5.6 IV antiarrhythmic drugs can be considered in stable patients with complex thycardia, especially suspected as VT VT having failed adenosine. Because of their longer duration of action, antiarrhythmic agents may also be useful to prevent recurrence of complex tachycardia. Lidocaine is not included as a treatment option for extensive unintentional complex tachycardia because it is a relatively narrow-spectrum remedy that is not effective for SVT, perhaps because its kinetic properties are less effective for VT at hemodynamic rates received from amiodarone, procainamide, or sotalol is .7-10 Different, amiodarone, procainamide, and sotalol is a broader spectrum of antiarrhythmics than lidocaine and is both can treat , but they can cause hypotension. Since the 2010 Guidelines, amiodarone's new branded bioequivalent formulation has been available for IV infusions with less hypotensive effects than older generic formulations.11 There have been some direct comparisons of effectiveness between amiodarone, procainamide, and sotalol itself.12 whose writing group felt was not enough to favor one of these other medications, in addition to being careful about its use in patients with long QT, amiodarone in suspected pre-excited arrhythmia, or give these medications in combination without consultation of a specialist first. Any of these drugs may also worsen the complex tachycardia, converting it to faster arrhythmias, less hemodynamic stable, or more malignant, until the availability of defibrillators is encouraged when these drugs are administered.13 Verapamil is a calcium channel blocking agents that delay the flow of AV nodes, shorten the refractory period of accessory pathways, and act as negative inotropic and vasodators. Its effects are between different mechanisms and longer survive than adenosine. Although effective for treating extensive complex tachycardia known as supraventricular origins and does not involve removal of accessory pathways, inotropic effects and negative hypotensive verapamil may affect VT14 and accelerate pre-excited atrial fibrillation and flutter.15 Similar concerns can also be used for other drugs commonly used to treat SVTs, such as diltiazem and β -adrenergic blockers, which are not handled in these recommendations and require evidence. The combination of slow-term AV flowing nodes, shortens refractory on myocardial pathways and accessories, and the hypotensive effect makes it inappropriate to unstable hemodynamic patients and to treat irregular tachycardias and extensive polymorphics. Adenosine only slows down rhythms of illaries, such as atrial fibrillation, causing it to be inappropriate for their management. Hypotensive and refractoriness-shortening drug tissue effects can accelerate ventricular rates in polymorphic VT and, when atrip or flutter fibrillation is carried out by accessory pathways, deterioration to VF.16 Therefore, drugs are not recommended in unstable hemodynamic patients or to treat regularly or tachycardias of a spacious polymorphic complex. This topic last received an official evidence review in 2010.17 of the Hemodynamics Core Electrical Management Recommendations Broad Tachycardia COR LOE Proposition 2a-C-LD 1. If pharmacological therapy is unsuccessful for the treatment of vast complex hemodial tachycardia, cardioversion or seeking an immediate specialist consultation is reasonable. Specific Recommendations Text Support When available, specialist consultations can assist in the diagnosis and management of tachycardia complexes of treatment-refractory. Electric cardioversion can be useful either as a first line treatment or for the complex tachycardia refractory of recent drugs due to entry rhythms (such as atrial fibrillation, atrial flutter, AV entry, and VT). However, electric cardioversion may be ineffective for automatic tachycardias (such as ectopic atrial tachycardias), requires risks associated with the drug edasi, and does not prevent the recurrence of complex tachycardia. Primarily, when the QRS complex is uniform morphology, shocks synchronized to QRS are encouraged as this minimizes the risk of triggering VF by the wrong surprise during the exposed period of the heart cycle (T waves).18 Different, polymorphic complex tachycardias cannot be synchronized resistant to it due to the different characteristics of each QRS complex, and requires high energy defibrillation.19 This topic last received an official evidence review in 2010.17 2.Torsades de Pointes Synopsis of the original ventricular tachycardia with a different configuration of the QRS complex from the beat to Beat. However, the most critical feature in polymorphic VT diagnosis and treatment is not rhythmic morphology but what is known (or suspected) about the patient's basic QT interval. Torsades de pointes is a form of polymorphic VT associated with prolonged heart rate of QT intervals when rhythm is normal and VT is absent. The risk of developing torsades increased as the corrected QT interval was greater than 500 milliseconds and accompanied by bradycardia.1 Torsades can be caused by inherited genetic abnormalities and can also be caused by medications and imbalances electrolytes that cause extending QT interval.3 Conver VT polymorphics not linked to long QT are most frequently caused by acute myocardial ischemia.4 .5 Other potential causes including polymorphic catecholaminergic VT , genetic abnormalities in which polymorphic VTs are promoted by exercise or emotion without the prolongation of QT; Short QT syndrome, a form of polymorphic VT linked to the incredible short QT interval (QT interval corrected less than 330-370 mignol)7.8 ; and VT dwakitions seen in digitalist toxicity where alternative QRS complex axes shift by 180 degrees.9 support data for acute pharmacological treatment VT polymorphics, with without length The QT interval, largely based on case reports and a series of cases, as no RCTs exist. Recommendation for Electrical Treatment Polymorphic VT COR LOE Recommendation 1-B-NR 1. Defibrillation is immediately recommended for sustainable, hemodynamic VT unstable. Special Support Text Recommendations Regardless of the basic QT interval, all forms of polymorphic VT tend to be hemodynamics and electricity are unstable. They can recur recur and send spontaneously, be sustainable, or deteriorate to VF, for which electric shocks may be required. When the QRS VT complex is a uniform morphology, electric cardioversion with shock synchronized to QRS minimizes the risk of triggering VF by wrong shock during the exposed period of the heart cycle (T Waves).10 Different, VT polymorphics cannot be synchronized for sure because different characteristics of each QRS complex and require defibrillation not to be synchronized with high energy.11 While effective in finishing polymorphic VT, electric shocks may not prevent its recurrence , for which pharmacological therapy is often required and the main focus of subsequent recommendations This topic was last received a review of official evidence in 2010.12 Recommendations for Pharmacological Treatment of VT-Related Polymorphics With Long QT Intervals (Torsades De Pointes) COR LOE Proposal 2b-CD. Magnesium can be considered for polymorphic VT treatments associated with long QT intervals (torsades de pointes). Suggestions Text Support Torsades de pointes usually present in recurrent patterns of self-termination, polymorphic VT haemodinations that are unstable in the context of known or suspected long QT abnormalities, often with related bradycardia. Immediate defibrillation is an optional treatment when torsades are maintained or deteriorated to VF. However, the termination of torsades by surprise does not prevent its recurrence, which requires additional measures. In a series of minor cases, IV magnesium has been effective in suppressing and preventing recurrence of torsades.13-16 Magnesium is believed to block early afterwards, which fluctuate in potential myocardous actions that can trigger VT salvos seen in torsades.17 Correct any abnormalities Torsades are not treated with antiarrhythmic drugs, which can prolong the QT interval and promote arrhythmia. When given acutely, β adrenergic blockers can also prosecute torsades by causing or aggravating bradycardia. In patients with bradycardia or paused presiding torsades, specialist consultations are best sought for additional measures such as overdrive pacing or isoproterenol.18-20 If needed. The use of magnesium in torsades de pointes was addressed by the 2010 Guidelines and updated in its 2018 focus update on ACLS.21 guidelines with an interim evidence review identifying no new information previous backup. This topic was last received in the study of official evidence in 2010.12 Reserves for The Treatment of Polymorphic Pharmacology VT Not Associated With Long QT Hoes COR LOE Reserve 2b-C-LD 1. IV lidocaine, amiodarone, and measures to treat myocardial ischemia may be considered to treat polymorphic VT without prolonged QT hoses. 3: No Benefit C-LD 2. We do not recommend regular use of magnesium for the treatment of polymorphic VT with regular QT hoses. Syor-Specific VT Polymorphic Support Texts that are not associated with QT lengthening are often triggered by acute myocardial ischemia and infarction.4,5 often rapidly degenerate into VF, and are treated similarly to other ventricular arrhythmias (VT and VF). However, the embedding of polymorphic VT with defibrillation may not prevent recurrence, which often requires additional measures. No RCTs have been performed to determine the best practices for the management of polymorphic VT pharmacology. However, measures to treat myocardial ischemia (e.g., β -adrenergic barriers or coronary cruelty interventions) as well as lidocaine and amiodarone may be effective.22-29 together with defibrillation when arrhythmias are maintained. β -Adrenergic blockers have also been shown to reduce the incidence of ventricular arrhythmias in acute coronary syndrome.30.31 Expert negotiations are advised when other polymorphic VT results are suspected, where the β -adrenergical and antiarrhythmics barriers may also have usefulness.6.32 This topic was last addressed by the 2010 Guidelines, with the current pack of interim evidence that identified no new information that would have changed the previous reserve. Newer diagnostic entities are estimated to lead to the assessment of future evidence of polymorphic VT. In the absence of long QT , magnesium was not shown to be effective in the polymorphic treatment of VT 13 or for benefits in the acute management of other ventricular tachyarrhythmias.16 This reserve supported by the current pack of 2018 which focused on the ACLS guidelines.21 7.3 Regular Narrow-Complex Tachycardia Introduction to SVTs Management is the subject of a recent joint treatment guidelines from the AHA, The American College of Cardiology, and the Heart Rhythm Society.1 Tachycardia's narrow complex represents a variety of tachyarrhythmias derived from a litar or pedesent involving atria or AV nod. The doctor must determine whether tachycardia is a complex or extensive tachycardia and if it has an ordinary or irregular rhythm. For patients with sinus tachycardia (heart rate greater than 100/min, P wave), no special drug treatment is required, and the doctor must focus on the identification and treatment of tachycardia basic stem (fever, dehydration, pain). If the patient is present with SVT, the main goal of treatment is to quickly identify and treat patients who are unstable hemodynamics (ischemic chest pain, altered mentality, surprises, acute heart failure) or symptoms due to arrhythmia. Cardioversion or synchronized medications or both can be used to control unstable tachycardia or common symptoms of narrow complexes. The available evidence shows that there is no available difference in success or the rate of major adverse events between calcium channel blockers and adenosine.2 In patients with narrow complex tachycardia that refractory to the measures described, this may indicate a more complicated rhythm of abnormalities for which expert consultations may be advised. Recommendations for Electrical Therapy for Tachycardia COR LOE Common Complex Proposal 1-B-NR 1. Synchronized cardioversion is recommended for acute treatment in patients with unstable hemodynamic SVT. 1-B-NR 2. Synchronized cardioversion is recommended for acute treatment in patients with stable hemodynamic SVT when vagal maneuvering and pharmacological therapy are ineffective or contraindicated. Specific Support Text Suggestions and 2. Unstable hemodynamic patient management with SVT must begin with an immediate restoration of sinus rhythm through cardioversion use. Cardioversion has been shown to be safe and effective in a prejudice setting for unstable hemodial patients with SVT who have failed to respond to vagal maneuvers and pharmacological therapy. IV 3 Cardioversion advised in patients present with hypotension, acutely altered mental status, shock signs, to the even if rare, cardioversion may also be The most stable patients with SVT have a high conversion success rate of 80% to 98% with pharmacological management (for example, adenosin, diltiazem).4,5 however, if the drugs fail to restore sinus rhythms, cardioversion is safe and effective for patients who are stable after adequate sedation and anaesthesia. The proposal is supported by the 2015 ACC/AHA/HRS Guidelines for Adult Patient Management With SVT: American College of Cardiology Report/ AHA Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 6 Recommendations for Pharmacological Therapy for Tachycardia COR LOE Common Narrow Complex Proposal 1-B-R 1. Vagal maneuvers are recommended for acute treatment in patients with SVT at a fixed rate. 1-B-R 2. Adenosine is recommended for acute treatment in patients with SVT at a fixed rate. 2a B-R 3. IV diltiazem or verapamil can be effective for acute treatment in patients with stable hemodynamic SVT at a fixed rate. 2a C-LD 4. IV β -adrenergic treatment is reasonable for acute treatment in patients with SVT with stable hemodynamic SVT at a fixed rate. Specific Support Text Rate Success for Valsalva's maneuver in terminating SVT ranges from 19% to 54%.7 Increasing Valsalva's maneuver with passive foot increase is more effective.8 Warnings are advised when using massage in older patients given the potential thromboembolic risks. 2015 2015 The Guidelines of the College Rhythm Society, AHA, and Cardiac Rhythm are evaluated and recommended adenosine as the first line treatment for a regular SVT due to its effectiveness, very short, and profitable side effect profiles.6 Systematic Study of Cochrane 7 RCTs (622 patients) found similar conversion rates to sinus rhythms with adenosine channel blockers and no significant difference in hypotension.2 Adenosine may have a profound effect in post-heart transplant patients and can cause severe bronchospasm in asthmatics. The treatment of stable haemlynyamic patients with IV diltiazem or verapamil has been shown to convert SVT into normal sinus rhythms in 64% to 98% of patients.98% patients.4.9–11 These agents are very useful in patients who cannot tolerate β -adrenergic blockers or who have SV Warnings should be taken to administer these drugs slowly to reduce the potential for hypotension.11 Diltiazem and verapamil inappropriate in setting suspected systolic heart failure.6 Evidence for β -adrenergic blockers in terminating SVT is limited. In an experiment that compares esmolol with diltiazem, diltiazem is more effective in ending SVT.5 however, β -adrenergic blockers are generally safe, and it is reasonable to use it to end SVT in stable hemodynamic patients.6 This proposal is supported by 2015 American College, AHA, and The Heart Rhythm Association's Guidelines for Adult Patient Management With SVT.6 7.4 Atrial Fibrillation or Flutter With Rapid Ventricle Response Introduction Fibrillation Atrium is an SVT consisting of unorthodox atrial electrical activation and contraction of uncoordinated atrial atrials. Atrial flutter is an SVT with a macroreentrant circuit that results in rapid atrium activation but intermittent ventricular response. These arrhythmias are common and often coexist, and the recommendations of their treatment are the same. The treatment of atrial fibrillation/flutter depends on the stability of the patient's hemodynamics as well as the previous history of arrhythmia, comorbidities, and responsiveness to medications. Hemodynamic patients are unstable and those with rate-related ischemia should receive immediate electrical cardioversion. Stable haemlynyamic patients can be treated with a rate control strategy or rhythm control. Rate control is more common in emergency settings, using the administration of IV calcium channels nondihydropyridine antagonists (for example, diltiazem, verapamil) or β -adrenergic blockers (for example, metoprolol, esmolol). Although amiodarone is usually considered a rhythm control agent, it can effectively reduce ventricle rates with potential consumption in patients with congestion heart failure where β -adrenergic may not be and nondihydropyridine calcium antagonist channels are contraindicated. Long-term anouagulation may be necessary for patients who are at risk for thromboembolic thromboembolic events at their CHA2 DS2 - VASC SCORE. Anticoagulation options are beyond the scope of these guidelines. Rhythm control strategies (sometimes called chemical cardioversion) include antiarrhythmic drugs given to convert rhythms to sinuses and/or prevent fibrillation/flutter recurrence of atrials (Table 3). The selection of patients, evaluation, time, drug selection, and anticoagulation for patients undergoing rhythm control are beyond the scope of these guidelines and are presented elsewhere.1.2 Patient management with preexcitation syndrome (aka Wolff-Parkinson-White) is protected in the Tachycardia Section of Broad Complex. Recommendations for Electrical Therapy for Atrial Fibrillation / Flutter COR LOE Proposition 1-C-LD 1. Hemodynamic patients are unstable with atrib fibrimedry or atrip flutter with a quick ventricle response should receive electric cardioversion. 1-C-LD 2. Direct current cardioversion immediately fibrillation of new atrials in setting acute coronary syndrome is recommended for patients with hemodynamic compromises, persistent ischaemics, or inadequate rate control. 2a C-LD 3. For cardioversion synchronized atrial fibrillation using biphasic energy, the initial energy of 120 to 200 J is reasonable, depending on the specific biphasic defibrillator used. 2b C-LD 4. For cardioversion synchronized flutter atrium using biphasic energy, the initial energy of 50 to 100 J may be reasonable, depending on the specific biphasic defibrillator used. Specific Support Text Suggestions and 2. Uncontrolled tachycardia can affect ventricle filling, heart output, and coronary perfluter while increasing the demand for myocardial oxygen. Although attempted medications and/or accelerated liquids may be appropriate in some cases, unstable patients or patients with persistent heart ischemia with atrial fibrillation or atrial flutter should be immediately contained.1-3 When deciding for cardioversion, one should also consider whether arrhythmia is the potential for rapid ventricle response hunting by secondary causes (for example, sepsis) should be considered and can inform an initial attempt at stabilization of hemodynamics with pharmacotherapy. There is some data addressing this strategy in hemodial patients unstable. However, studies showing the benefits of successful cardioversion hemodynamics have been published.4.5 In addition, Hypothermic and hypophosical risks with negative inotrope consumption have been indicated even in normotensive patients.6-8 Unstable Hemodynamic patients and those with persistent heart iscopy may benefit from better haemdy status associated with sinus rhythm restoration and avoid hypotension caused by alternative pharmacological therapy. Depending on the clinical scenario, patients dedicated to atrial fibrillation or atrial flutter 48 or longer is the candidate for anticoagulants. Granules Anticoagulation selection is available elsewhere.2 and 4. The electricity needed to succeed cardiovert patients from atrial fibrillation or atrial flutter to sinus rhythms varies and generally less in patients with new arrhythmia, thin body habits, and when biphasic wave shocks are delivered.9-15 Obese patients may need greater energy.16 If early cardioversion is not successful Less energy is usually required for atrial flutter than atrial fibrillation.11 Energy higher 200 J or more associated with better first shock success and decreased energy delivery volume. In addition, retrospective analysis found that lower energy shocks were associated with a higher risk of VF.17 Guidelines caused by cardioversion including comparison of monophasic and biphasic waves. The proposal now focuses primarily on biphasic waves. The recommended energy levels vary with different devices, reducing the validity of general recommendations. This topic requires further research with a comprehensive systematic review to better understand the optimal dose of electricity with the current device. The assessment of the LOE writing group as A C-LD is consistent with limited evidence using modern devices and energy waves. The proposal is supported by the AHA/ACC/HRS 2014 Guidelines for Patient Management With Atrial Fibrillation: The American College of Cardiology Report/ AHA Task Force on the Practice Guidelines and Heart Rhy of the Athletic Association 2018 as well as focus updates on guidelines published in 2019.2 Recommendations for Medical Therapy for Medical Therapies for Medical Facilities for Atrial Fibrillation/Flutter IV administration of β -adrenergic blocker or nondihydropyridine calcium antagonist channel is recommended to slow the ventricle heart rate in acute settings in patients with atrial fibrillation or atrial flutter with a rapid ventricle response without preexcitation. 2a B-NR 2. IV amiodarone can be useful for rate control in critically ill patients with atrial fibrillation with a rapid ventricle response without preexcitation. 3: C-LD Harm 3. In patients with atrial fibrildegies and atrial flutters in preexcitation settings, digoxin, nondihydropyridine calcium tract antagonists, β -adrenergic blockers, and IV amiodarone cannot be administered because they can increase ventricular response and cause 3: Harm C-EO 4. Calcium nondihydropyridine channel antagonists and IV blockers β -adrenergic should not be used in patients with left ventricle systolic dysfunction and disconnected heart failure as this could lead to further hemodynamic compromises. Specific Support Text Suggestions and 2. Clinical trial evidence suggests that the antagonists of the nondihydropyridine calcium channel (for example, diltiazem, adrenergic drug β (for example, esmolol, propranolol), amiodarone, and digoxin are all effective for rate control with atrial fibrillation/flutter.6-8.19-23 Calcium channel blockers may be more effective than amiodarone, and cause more hypotension.6 Digoxin rarely used in acute environments because of the slow start of the effect.1.2 Based on limited case reports and small cases series, There are fears that patients with preexcitation and atrial fibrillation or atrial flutter can develop VF in response to an accelerated ventricle response after the administration of AV nodes blocked agents such as digoxin, nondihydropyridine calcium tract antagonists, β adrenergic blockers, or IV amiodarone.24-27 In this setting, cardioversion is recommended as the most appropriate management. Because of their negative inotropic effects, nondihydropyridine calcium tract antagonists (for example, diltiazem, verapamil) can decay patients with left ventricular cystolic dysfunction and heart failure symptoms. They can be used in patients with heart failure with a breakdown of preserved mocking β adrenergic blockers can be used in compensation patients with cardiomyopathy; However, they should be used with caution or avoidance altogether in patients with disconnected heart failure. This recommendation is based on expert consensus and rationale for pathophysiological.2.18,28 β -Adrenergic blockers can be used in patients with chronic obstructive chone disease as some studies have shown no negative effects.29 This proposal is supported by AHA 2014, American College of Cardiology, and Heart Rhythm Society Guideline for Management of Patients With Atrial Fibrillation18 as well as guidelines focused on guidelines published in 2019.2 7.5 Bradycardia Introduction Bradycardia is generally defined as a heart rate of less than 60/min. Bradycardia can be a common discovery, especially for athletes or during sleep. When bradycardia occurs secondary to pathological causes, it can lead to a decrease in heart output with the resulting hypotension and tissue hypoperfusion. Clinical manifestations of bradycardia can range from the absence of symptoms to bradycardia symptoms (bradycardia associated with acutely altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or other signs of persistent shock even if the cause of bradycardia can determine the severity of the show. For example, patients with severe hypoxia and upcoming respiratory failure can suddenly develop deep bradycardia that leads to cardiac arrest if not handled immediately. On the other hand, patients developing third-degree heart blocks but otherwise good compensation may suffer relatively low blood pressure but otherwise stable. Therefore, the management of bradycardia depends on both the underlying cause and the severity of the clinical presentation. In 2018, AHA, American College of and the Heart Rhythm Society publishes a broad guideline on stable assessment and management and bradycardia.2 These guidelines focus exclusively on bradycardia symptoms in ACLS settings and maintain consistency with the 2018 guidelines. Proposal for Bradycardia COR Electrical Management LOE Proposition 1-C-EO 1. In patients present with bradycardia acute symptoms, evaluation and treatment of reversible causes are recommended. 2a B-NR 2. In patients with acute bradycardia linked to hemodynamic compromises, the administration of atropine is reasonable to increase heart rate. 2b C-LD 3. If bradycardia is not responsible for atropine, IV adrenergic agonists with effects accelerate rates (for example, epinephrine) or transcutaneous pacing may be effective while patients are ready to temporarily pacing survival if needed. 2b C-EO 4. Immediate pacing can be considered in unstable patients with high degree AV blocks when IV/IO access is unavailable. Bradycardia Symptom Support Text Recommendations may be caused by a number of potentially reversible or treatable causes, including structural heart disease, increased vagal tones, hypoxemia, myocardial ischaemia, or drugs.2 Bradycardia may be difficult to settle until the underlying cause is treated, makes the foundation's assessment Atropine has proven effective for bradycardia symptom treatment in both observational studies and in 1 limited RCT.3-7 If atropine is ineffective, either an alternative agent for increasing heart rate and blood pressure or transcutaneous pacing are reasonable next steps. For the medical management of periarrest patients, epinephrine has gained popularity, including IV absorption and use of push-dose administration for acute bradycardia and hypotension. Studies on push-dose epinephrine for bradycardia in particular are less, although limited data support its use for hypotension.8 Use of push-dose vasopressors requires careful attention to correct the dose. Drug errors leading to adverse effects have been reported.9 Dopamine infusions may also increase heart rate.10 There are limited studies that compare drugs to transcutaneous pacing for bradycardia treatment. A random feasibility study in patients failed atrial flutter versus dopamine to transcutaneous pacing and found no difference in survival for discharge.10 Whether for transcutaneous pacing attempts, epinephrine, dopamine, or other vasoactive agents will likely rely on clinician experiences and available resources. For bradycardia severe symptoms cause shock, if no IV or IO access is available, immediate transcutaneous pacing while access is being run can be carried out. A 2006 systematic review involving 7 transcutaneous pacing studies for bradycardia symptoms and arrest bradyasystolic in a prehospital atmosphere found no benefit from pacing compared to standard ACLS, although subgroup analysis of 1 attempt suggests Benefits in patients with bradycardia symptoms.11 This proposal is supported by 2018 ACC/AHA/HRS Guidelines on Assessment and Patient Management With Bradycardia and Heart Conduction Delays: Cardiology College Report / AHA Task Force America on Clinical Practice Guidelines and The Heart Rhythm Society. 2 Proposal for Transvenous Pacing for Bradycardia COR LOE Proposition 2a C-LD 1. In patients with continuous haemorrhidia refractory to medical therapy, transvenous pacing while it is reasonable to increase heart rate and improve symptoms. Specific Support Text Recommendations When bradycardia refractory to medical management and results in severe symptoms, the next reasonable step is the placement of temporary catheter pacing for transvenous pacing. Limited evidence for this intervention consists of an observational study, many of which have focused on relatively high indicators and complication rates (including blood flow infections and pneumothorax, among others).12-14 However, when the heart rate does not improve with medication and continuous shock, Transvenous pacing can increase heart rate and symptoms until more definitive treatment (correction of base cause or permanent pacemaker placement) can be implemented this recommendation is supported by the Guidelines of the American College of Cardiology 2018, AHA, and Heart Rhythm The Society on patient assessment and management with bradycardia and cardiac flow delays.2 7.6 Care After Rosc Postresuscitation Care Introduction Post-heart care arrest is a critical component of the Survival chain. What defines optimal hospital care for patients with ROSC after cardiac arrest is not fully known, but there is a growing interest in identifying and optimizing practices that might improve outcomes. The systemic effects of ischaemic injuries caused by cardiac arrest and subsequent resuscitation require post-cardiac arrest care to support the affected multi-organ system. After initial stabilization, the care of critically ill posarrest patients rallied on hemodynamic support, mechanical ventilation, temperature management, diagnosis and treatment of underlying causes, diagnosis and treatment of seizures, fumigation for and treatment of infections, and the management of critical conditions of the patient. Many patients who catch the heart survivors of the initial incident will eventually die due to lifelong withdrawal of treatment in the setting of a nerve injury. The cause of this death is very prominent in those with OHCA but also frequently after IHCA.1.2 Therefore, many posarrest care focuses on reducing injuries to the brain. Possible contributors to this goal include fiber perfume pressure optimization, oxygen and carbon dioxide level management, temperature control core, and detection and treatment of seizures (Fig. 9). 9). arrests resulted in heterogeneous injuries; therefore, death can also be caused by multiorgan dysfunction or shock. Given the complexity of posarrest patients, multi-disciplinary teams with expertise in cardiac arrest care are prioritised, and the development of multi-disciplinary protocols is critical to optimizing the results of survival and neurology. Key topics in postresuscitation care were not covered in this section, but discussed later, targeted temperature management (TTM) (Targeted Temperature Management), quantity coronary intervention (PCI) in cardiac arrest (PCI After Cardiac Arrest), neuroprognostication (Neuroprognostication), and rehabilitation (Rehabilitation). Recommendations For Consideration during the Initial Postresuscitation Period COR LOE Proposition 1-B-NR 1. A comprehensive, organized, multi-disciplinary care system should be implemented consistently for the treatment of post-cardiac arrest patients. 1-B-NR 2. A 12-lead ECG should be obtained as soon as possible after the ROSC to determine whether the acute ST segment height is present. 2a C-EO 3. To prevent hypoxia in adults with ROSC during the immediate posarrest period, it is reasonable to use the highest concentration of oxygen until the saturation of the arteries oxyhemoglobin or partial pressure of artery oxygen can be measured remarkably. Specific Support Text Studies Observations assessed the utility of cardiac acceptance centers indicating that a strong care system could represent a logical clinical relationship between successful resuscitation and ultimate survival.3 Although data is limited, taken along with experiences from regional approaches to other emergencies such as trauma, stroke, and st-height infra Patients with 12-lead identification of myocardial infarction st-segment (STEMI) should have coronary angiography for possible PCI, highlighting the importance of obtaining the ECG for diagnostic purposes.4 However, Various studies have reported that the absence of ST-segment height does not rule out coronary lesions that can intervene.5-7 Some RCTs have compared the oxygen administration's titrated approach to the approach of administering 100% oxygen in the first 1 to 2 hours after the ROSC.8-10 All this carried out prejudice settings. However, these tests are only titrated oxygen once saturated oxygen can be measured with pulse oxymeter. No studies have investigated oxygen titration in patients whose oxygen saturation (by pulse oxymeter) or semi-oxygen pressure in the blood (by arterial blood gas) cannot be measured. Recommendations for administering 100% oxygen until the measurement of this important sign is possible based on physiology and expert opinion that hypoxia can worsen the damage of the final organ and should be avoided. Recommendation 1 supported Updates focused on the ACLS.3 Recommendation 2 guidelines last received an official evidence review in 2015.4 Recommendation 3 supported by CoSTR 2020 for ALS.11 Blood pressure management recommendations after the ROSC COR LOE Recommendation 2a-BNR 1. It is best to avoid hypotension by maintaining siccilic blood pressure of at least 90 mm Hg and mean arterial pressure of at least 65 mm Hg during the period of postresuscitation. Hypotension Text-Specific Recommendations can worsen the brain and other organ injuries after cardiac arrest by reducing oxygen transmission to tissues. The optimal PETA target after the ROSC, however, is unclear. The topic was previously reviewed by ILCOR in 2015.12 and a detailed evidence update was conducted by the Australian and New Zealand Resuscitation Council on behalf of ILCOR for 2020.11 Some Observational studies have found that postresuscitation hypotension is associated with worse survival and neurological outcomes.13-19 A study found no association between higher PETA during treatment and TTM results , although the current shock of admission is associated with poor results.20 Hypotension definition varies between studies, with systolic blood pressure of 90 mm Hg and MAP 65 mm Hg commonly used. Two RCT conducted since 2015 compared to low blood pressure targets (standard care or MAP greater than 65 mm Hg in one study and MAP 65-75 mm Hg on the other side) with higher targets (MAP 85-100 in one study and MAP 80-100 mm Hg in another).21.22 Both studies failed to detect any differences in survival or survival with encouraging neurological outcomes , although insane studies are not appropriately enlarged for this outcome. An experiment has found an increase in cerebral oxygen with a higher MAP.21 which is a proposed mechanism for the effects of higher MAP benefits in hypoxic ischaemic encephalopathy. A recent observational study compared results in patients with MAP 70 to 90 mm Hg to those with MAPs larger than 90 mm Hg also found that higher PETA was associated with better neurological outcomes.23 Although some of these data suggested targeting MAPs of 80 mm Hg or higher in those at risk for cardiac neurological injuries may be beneficial, this remains undeterred. The recommendations are supported by the Updated Guidelines 24 2015 and the 2020.11 evidence updates of proposals for Oxygenation and Ventilation After ROSC COR LOE Proposed 1-B-NR 1. We recommend avoiding hypoxemia in all patients who remain comatose after ROSC. 2b B-R 2. Once a reliable measurement of peripheral blood oxygen saturation is available, avoiding hyperoxemia by typing in inspired oxygen breakdown to target oxygen saturation 92% to 98% may be reasonable on which remains comatose after the ROSC. 2b B-R 3. Maintaining partial pressure of carbon dioxide arteries (Paco2) in the usual physiological range (generally 35-45 mm Hg) may be reasonable in patients who remain comatose after ROSC. Recommendations of Recommendations Text In a systematic study of ILCOR 2020.11 observational studies reported that hypoxemia after circulation returns were associated with worse outcomes.25 This was not seen in other studies.26-28 and all high-risk biased studies. Therefore, these recommendations are based primarily on the physiological rationale that hypoxia increases the risk of final organ damage, and the fact that hypoxemia is the best surrogate available for hypoxia. There are some physiological and preclinical data for hyperoxemia leading to increased inflammation and exacerbating brain injuries in posarrest.29 A 2020 ILCOR systematic study11 identifies 5 meddling RCTs compare titrated or lower oxygen administration strategies with regular care or higher oxygen administration strategies in posarrest patients: 3 in prehospital environments and 2 in ICU settings.8-10,30,31 Overall , these tests found no difference in clinical outcomes, but all were less leasing for these outcomes. Large RCT recently compared regular care with aggressive ectlogophroxy in mechanical ventilation critical patients and found no difference between groups in overall cohorts but increased survival on the arm intervened in subgroups 164 patient posts.32 Observation data is inconsistent and very limited by confounding.11 Three RCTs on this topic under progress (NCT03138005, NCT03653325, NCT03141099). The proposed range of 92% to 98% is meant as a practical estimate of the normal range. Two RCTs compare strategies targeting Highnormal Paco2 (44-46 mmHg) with one targeting low normal Paco2 (33–35 mmHg)31 and hi strategy targets Moderatercapnia (Paco2 50- 55 mmHg) compared to normocapnia (Paco2 35-45 mmHg).33 No attempt finds a difference in any clinical outcome. Results across

rates may be slow or difficult to detect,13.14 and the ECG may also show asystole, making it important to perform life-saving interventions until the victim is warm and/or clearly dead. Because severe hypothermia is often affected by other disorders (for example, the overdose of drugs, alcohol consumption, trauma), it is advisable to find and treat this basic condition and at the same time treat the hypothermia. The hypothermic heart may not be responsible for cardiovascular drugs, pacemaker stimulation, and defibrillation; However, the data to support this is essentially theoretical.15 If VT or VF continues after a single shock, the value delays subsequent defibrillations until the target temperature is reached volatile. There is no evidence to benefit from deviating from standard BLS protocols for defibrillation. Evidence in human effects of vasopressors or other medications during cardiac arrest in hypothermia setting consists of case-only reports.11,16,17 Systematic studies of several animal studies concluded that the use of vasopressors during hypothermic cardiac arrest increases ROSC.18 No evidence identified at the time of review including vasopressor medications, during hypothermic cardiac arrest. This topic last time received an official evidence review in 2010.1 9.2 IntroductionAnaphylaxis Between 1.6% and 5.1% of US adults have experienced anaphylaxis.1 About 200 Americans die from anaphylaxis each year, mostly from adverse reactions to medications.2 Although anaphylaxis is a multisystem disease, life-threatening manifestations most often involve respiratory tract (edema, bronchospasm) and/or circulatory system (vasodilatory shock). Epinephrine is the basis of treatment for anaphylaxis.3-5 Recommendations for Heart Of Anaphylaxis COR LOE Syor 1 C-LD 1. In secondary cardiac arrest to anaphylaxis, standard resuscitation measures and the immediate administration of epinephrine should take priority. Special Support Backup Backup No RCTs assess alternative treatment algorithms for cardiac arrest because of anaphylaxis. Evidence is limited to case reports and extrapolations from non-face cases, pathophysiological interpretations, and consensus opinions. Immediate support of airways, breathing, and blood circulation is essential in suspected anaphylactic reactions. Due to limited evidence, the secondary cardiac arrest management base to anaphylaxis is standard BLS and ACLS, including early airway management and epinephrine. There are no proven benefits from the use of antihistamines, inhaled beta agonists, and IV corticosteroids during cardiac arrest caused by anaphylaxis. Recommendations for Anaphylaxis Without Cardiac Capture COR LOE Proposition 1 C-LD 1. Epinephrine should be administered early by intramuscular injections (or autoinjector) to all patients with signs of systemic allergic reactions, especially hypotensions, swelling of airways, or breathing difficulties. 1 C-LD 2. The recommended dose of epinephrine in anaphylaxis is 0.2 to 0.5 mg (0.1-1000) intramuscular, which will be repeated every 5 to 15 minutes as needed. 1 C-LD 3. In patients with anaphylactic shock, close hemodynamic monitoring is recommended. 1 C-LD 4. Given the potential for rapid development of oropharyngeal or laryngeal edema, an immediate reference to health professionals with expertise in advanced airway placement, including surgical airway management, is recommended. 2a C-LD 5. When the IV line is provided, it is reasonable to consider the IV route for epinephrine in anaphylactic shock, at doses 0.05 to 0.1 mg (0.1 mg/mL, aka 1:10 000). 2a C-LD 6. IV absorption of epinephrine is a reasonable alternative to IV boluses for the treatment of anaphylaxis in patients who are not in cardiac arrest. 2b C-LD 7. IV absorption of epinephrine can be considered for shock after catch in patients with anaphylaxis. Recommendations Of Supporting All Patients with Anaphylaxis evidence require early treatment with epinephrine. Severe anaphylaxis can cause complete obstruction of airways and/or cardiovascular collapsing from vasogenic shock. The administration of epinephrine may save lives.6 Intramuscular is the early route of choice due to the convenience of administration, effectiveness, and safety.7 Injections of epinephrine into the lateral aspect of the thigh produces the rapid concentration of epinephrine plasma.7 Autoinjector intramuscular epinephrine and the paediatric epinephrine autoinjector intramuscular will deliver 0.15 mg of epinephrine. Many patients will need an additional dose, with recurrence of symptoms after 5 to 15 minutes reported.8 Patients in anaphylactic shock critical pain, and cardiovascular and respiratory status can change quickly, making close monitoring of imperative.9 When anaphylaxis produces edema obstructive air management, rapid air management in some cases, emergency cricothyroidotomy or tracheostomy may be required.10,11 epinephrine is a suitable alternative to intramuscular administration in anaphylactic shock when IV is prepared. The dose of IV 0.05 to 0.1 mg (5% to 10% of the dose of epinephrine used routinely in cardiac arrest) was used successfully for anaphylactic shock.9 Although not specifically studied by this path in anaphylaxis, IO epinephrine may also be effective at comparison In anaphylactic shock canine models, the constant absorption of epinephrine is more effective for treating hypotension than no treatment or treatment of epinephrine bolus is.12 If the shock recurrences after early treatment, infusion IV (5-15 µg/min) can also allow caution to titration and avoid overdose Although specific data for patients with ROSC after cardiac arrest from anaphylaxis is not identified, an anaphylactic shock observation study suggests that IV infusion of epinephrine (5-15 µg/min), along with other resuscitation measures such as volume resuscitation, can be successful in the treatment of anaphylactic shock.13 Because of its role in the treatment of anaphylaxis , epinephrine is a logical option for postarrest shock treatment in this environment. This topic was last received an official evidence review in 2010.14 9.3 ArrestCardiac Due to Asthma Proposal for Cardiac Arrest Management Due to Asthma COR LOE Proposition 1 C-LD 1. For asthma patients with cardiac arrest, sudden height in peak inspirational pressure or ventilation difficulties should immediately evaluate for pneumothorax tension. 2a C-LD 2. Due to the potential effects of positive intrinsic pressure expired (auto-PEEP) and the risk of barotrauma in asthma patients with cardiac arrest, the ventilation strategy of low respiratory rates and neat volume is reasonable. 2a C-LD 3. If an auto-PEEP increase or sudden decrease in blood pressure is included in asthma that receives assisted ventilation in peri-arrest conditions, brief cuts from bag masks or ventilators with chest wall compression to relieve air trapping can be effective. Severe asthma attacks can lead to deep respiratory distress, carbon dioxide retention, and air trapping, causing acute respiratory acidosis and high intrathoracic pressure. Death from acute asthma has decreased in the United States, but asthma continues to be a cause of acute death for over 3500 adults a year.1,2 Patients with respiratory arrest from asthma develop acute respiratory acidosis life threatening.3 Both deep acidemia and reduced venous return to heart from high intrathoracic stress may be caused The care of any patient with cardiac arrest in the setting of asthma acute hunting begins with standard BLS. There are also no specific changes to ACLS for with cardiac arrest from asthma, despite airway management and increased significant ventilation given the possibility of causes of respiratory arrest. Acute asthma management was reviewed in detail in the 2010.4 Guidelines for 2020, the writing group focused on additional considerations of ACLS specifically for asthmatics during the immediate peri-arrest period. Text Support Pneumothorax strain is a rare complication of life-threatening asthma and the cause of potentially reversible arrest.5 Although usually occurs in patients receiving mechanical ventilation, cases of spontaneous respiratory patients have reported.5-7 High peak airway pressure resulting from ventilation While difficulty in narrative asthma patients in extremis is more likely to be caused by high hyperinflation and intrathoracic stress, the assessment for tension pneumothorax remains important. Acute respiratory failure that can claim cardiac arrest in asthma patients is characterized by severe obstacles leading to air trapping. Due to limitations in incredible airflow, large tidal volume transmission at higher respiratory rates can lead to progressive air trapping and effective decrease in ventilation. Approach using lower neat volume, lower respiratory rates, and increased expiration times can minimize the risk of auto-PEEP and barotrauma.8 Breath compelling asthma patients with limited ability to sniff can lead to increased intrathoracic pressure. Decrease in venous returns and coronary perfume pressure, and cardiac arrest.9-11 This can be real due to increased difficulty in ventilators, alarms of high airway pressure on ventilators, or sudden drops in blood pressure. Brief cuts from ventilators or pauses in the ventilation of bag masks and thorax compression to help refinement can relieve hyperinflation. This topic was last received an official evidence review in 2010.4 9.4 ArrestCardiac After Proposed Cardiac Surgery for Cardiac Arrest After Cardiac Surgery COR LOE Proposed 1 B-NR 1. External chest compression should be done if emergency resternotomi is not immediately available. 1 C-LD 2. In the arrests testified by a trained provider of post-heart surgery patients, an immediate defibrillation for VF/VT should be done. CPR should start if defibrillation is unsuccessful within 1 min. In the arrests faxed by a trained supplier of post-cardiac surgery patients where pacer wires are already available, we recommend immediate pacing in asystolic or bradycardic arrests. CPR should start if the pacing is unsuccessful within 1 min. 2a B-NR 4. For patients with cardiac arrest after cardiac surgery, it is reasonable to perform an early resternotomi in an ICU that is on duty and equipped Appropriate. 2a C-LD 5. Open chest CPR can be useful if cardiac arrest develops during surgery when the chest or stomach is already open, or in the postoperative period early after cardioprotection surgery. 2b C-LD 6. In post-heart surgery patients who are to standard resuscitation procedures, mechanical blood circulation support may be effective in increasing yield. Synopsis Cardiac Arrest occurs after 1% to 8% of cases of heart surgery.1-8 Etiologies including tachyarrhythmias such as VT or VF, bradyarrhythmias such as heart blocks or asystole, obstructive causes such as tamponade or pneumothorax, technical factors such as new valve dysfunction, inclusion of growing arteries, or bleeding. Like all patients with cardiac arrest, the immediate goal is the recovery of perfuser with CPR, the onset of ACLS, and rapid identification and correction of the cause of cardiac arrest. Unlike most other cardiac arrests, these patients usually develop cardiac arrest in highly monitored environments such as ICU, with highly trained staff available to perform rescue therapies. These guidelines are not intended to be comprehensive. A recent consensus statement on the topic was published by the Thoracic Surgeons Association.9 The Specific Support Text Case Report has rarely described damage to the heart due to the compression of the external chest.10-14 However, other case series did not report such damage,8 and external chest compression remained the only way of preparing perfume in some form. In this case, the risk of compression of the external chest is much greater than that of a certain death in the absence of perfumery. VF is a presentation rhythm in 25% to 50% of cases of cardiac arrest after heart surgery. Immediate defibrillation by trained suppliers presents different advantages in these patients, while morbidity associated with external chest compression or resternotomy can have a significant recovery effect. Sparse data has been published addressing this question. Limited data is available from defibrillator threshold tests with backup transthoracic defibrillation, using variable wave forms and energy doses.15-17 First shock success of more than 90% has been observed in most of these studies, although the results collected from 15 studies found a success rate of 78% defibrillation for the first surprise, 35% for the second, and 14% for the third shock.18 Association of Thoracic Surgeons Task Force on Resuscitation After Heart Surgery9 and the European Society for Cardio-Thoracic18 Surgery recommended 3 compiled defibrillation in 1 minute , before starting CPR. Departure from the ACLS of this standard may be warranted in post-heart surgical settings due to highly monitored settings and unique risks of compression and resternotomi. In post-heart surgery patients with asistole or bradycardic arrests in the ICU with on-site pacing indicators, pacing can be started immediately by a trained supplier. Haemdy monitoring modalities available in conjunction with manual pulse detection opportunity to confirm the myocardial capture and adequate functioning of the heart. When the pacing attempt was not immediately successful, standard ACLS including CPR was shown. This protocol is supported by society,9,18 although no data is available to support its use. No resternotomi time RCTs have been done. However, good results were observed with rapid resternotomi protocols when performed by experienced suppliers in ICU.1,4,8,19-25 Other studies were neutral or showed no benefits of resternotomi compared to standard therapy.3,6,26,27 Resternot done outside the ICU decision in poor results.1,3 The Thoracic Surgeons Association recommends that resternotomi be the standard part of the resuscitation protocol for at least 10 days after the surgery.9 No random RCTs have been performed comparing open chests with external CPR. Two minor studies have shown an increase in the effects of open chest CPR when compared to external chest compression in heart surgery patients.3,4 A series of double cases have shown potential benefits from mercaran circulation accumulation of support including ECMO and cardiopulmonary bypass in patients refractory to standard resuscitation procedures.24,28-34 No RCT has been performed to date. This topic was last received an official evidence review in 2010.35 this proposal plus a 2017 review published by the Thoracic Surgeons Association.9 9.5Drowning Proposals to Drown COR LOE Proposition 1 C-LD 1. Rescuers should provide CPR, including rescue breathing, once the victim is unspiculously submerged removed from the water. 1 C-LD 2. All drowning victims requiring any form of resuscitation (including rescue breathing only) should be transported to hospital for evaluation and monitoring, despite appearing to be on alert and showing effective cardiorespiratory functions at the scene. 2b C-LD 3. Mouth-to-mouth ventilation in the water may be useful when administered by trained rescuers if it does not compromise safety. 3 No Benefit b-NR 4. Cervical spine routine stabilization without conditions suggesting spinal injuries are not recommended. Synopsis Every year, drowning is responsible for about 0.7% of deaths worldwide, or more than 500 000 deaths a year.1,2 Recent studies using data from the United States reported a survival rate of 13% after cardiac arrest related to drowning.3 People who were at high risk of drowning including children, those with seizure disorders, and those who were intoxicated with alcohol or other medications.1 Even though survival was unusual , successful resuscitation has been reported.4-9 For this reason, scene resuscitation should be initiated and the victim is transported to hospital unless there are clear signs of death. Standard BLS and ACLS are the basis of treatment, with airway management and ventilation very important due to the cause of respiratory arrest. Evidence for this proposal was last studied carefully in 2010. Recommendations of Duration Support Text and the severity of the hypoxia maintained as drowning is the single most important determinant of the outcome.10,11 With the result, once the unspiculous submerged victim is removed from the water, rescuers should provide CPR, with rescue breathing, if trained accordingly. The immediate start of rescue breathing increases the chances of victims to survive.12 Double observational assessments, especially in pediatric patients, have shown that decompression after drowning of fresh water or salt can occur in the first 4 to 6 hours after the events.13,14 This supports transporting all victims to medical facilities for monitoring at least 4 to 6 hours if possible The immediate cause of death drowning is hypoxemia. Based on rescue training, and only if the safety of the scene can be maintained for rescuers, sometimes ventilation can be provided in water (underwater resuscitation), which can lead to better patient outcomes compared to ventilation delays until the victim is out of the water.8 Incidents of cervical spinal injuries reported in drowning victims are low 15.16 Routine stabilization of the cervical spine in the absence of a condition that suggests spinal injuries are unlikely to be beneficial to patients and possibly the necessary delays in resuscitation.16,17 This proposal incorporates the results of CoSTR ILCOR 2020, which focuses on prognostic factors in drowning.18 Otherwise, this topic last time received a formal evidence review in 2010.19 These guidelines are added to the Wilderness Medical Society. Clinical Practice Guidelines for Drowning Treatment and Prevention: Update 2019. 20 9.6 Abnormalities Proposal for Electrolyte Abnormalities in Cardiac Catch COR LOE Proposition 1 C-LD 1. For cardiac arrest with known or suspected hypercaemia, in addition to standard ACLS care, calcium IV should be administered. 1 C-LD 2. For cardiotoxicity and cardiac arrest from severe hypomagnesemia, in addition to standard ACLS care, magnesium IV is recommended. 2b C-EO 3. For cardiac arrest with known or suspected hypermagnesemia, in addition to standard ACLS care, it may be reasonable to administer empirical calcium IV. 3: C-LD Harm 4. IV potent administrative bolus for cardiac arrest in suspected hypocalcemia is not recommended. Synopsis Electrolyte abnormalities may cause or contribute to cardiac arrest, hinder resuscitation efforts, and affect hemodynamic rehabilitation after cardiac arrest. In addition to standard ACLS, certain interventions may save lives for cases of hypercaemia and hypermagnesemia. Hyperkalemia is usually caused by kidney failure and can precede cardiac arrhythmia and cardiac arrest. Clinical signs associated with hypercaemia severe (more than 6.5 mmol/L) including complicate paralysis, paresthesia, depressed tendon reflexes, or shortness of breath.1-3 Early signs of electrolytic including T-escalation waves on the ECG followed by flat or absent T waves, prolonged PR PS intervals, widening QRS deep S waves, and the merger of S and T.4,5 waves As hypercaemia progresses, ECG can develop idioventricular rhythms, forming spinal wave patterns, and developing into severe asthmocolic cardiac arrest.4,5 Hypokalemia is less common but can occur in the setting of gastrointestinal or kidney losses and can lead to life-threatening ventricle arrhythmia.6-8 Severe hypomagnesemia is likely to occur in an obstetric environment in patients being treated with magnesium IV At a very high level, hypermagnesemia can lead to altered awareness, bradycardia or ventricle arrhythmias, and cardiac arrest.9,10 Hypomagnesemia can occur in the setting of gastrointestinal or malnutrition diseases, among other causes, and, when significant, can lead to both atrial and arrhythmia ventricles.11 Recommendations-Specific Support Texts Other than ACLS standard, some therapies have long been recommended to treat life-threatening hypercaemia.12 This includes the administration of IV calcium and/or bikarbonate, insulin with glucoseosa, and/or parental Calcium alhal can stabilize the myocardial insert membrane and therefore most likely to be useful during cardiac arrest and can be given by route IV or IO. The usual dose is 5 to 10 mL of 10% calcium chloride solution, or 15 to 30 mL solution 10% gluconate calcium, administered via IV or IO lines over 2 to 5 minutes.12 The use of sodium polystyrene standards (Kayexalate) is now not restored due to poor efficacy and risk of intestinal complications. Haemodialysis of cumulation in hospital environments remains the ultimate treatment for life-threatening hypercaemia. Although the magnesium IV administration has not been found to be beneficial for VF/VT in the absence of a prolonged QT, consideration of its use for cardiac arrest in patients with prolonged QT advised.13 Hypomagnesemia may cause or aggravate prolonged QT, linked to various arrhythmias, and can precede cardiac arrest.11 This provides a physiological rationale for normal level rehabilitation, although the ACLS remains the basis of treatment. Recommendations for treatment of torsades de pointes are provided in the Tachycardia Section of the Broad Complex. The administration of IV or CALCIUM IO, in the recommended dose for hypercaemia, can increase haemdy in severe magnesium toxicity, supports its use in cardiac arrest despite direct evidence of less.14 potassium-controlled administration of IV for ventricle arrhythmias because severe hypocalcemia can be used, but case reports generally include potassium absorption and not bolus dose.15 Bolus dose without adverse heart effects reported in at least 1 series of minor cases of heart surgery patients where it is administered but this effectiveness for cardiac arrest is unknown, and security concerns remain.16 This topic last received official evidence in 2010.12 9.7Opioid Overdose The continuous introduction of the opioid epidemic resulted in an increase in opioid-related OHCA. Leads to about 115 deaths per day in the United States and mostly affect patients from 25 to 65 years.1-3 Initially, isolated opioid toxicity is associated with CNS and protracted respiratory depression to respiratory arrest followed by cardiac arrest. Most opioid-related deaths also involve coding various drugs or medicines and mental health comorbidities.4-7 In creating these recommendations, the writing group considers the difficulty in distinguishing opioid-related resuscitation emergencies from other causes of cardiac arrest and breathing. An opioid-related resuscitation emergency is defined by the presence of cardiac arrest, respiratory arrest, or severe life-threatening instability (such as severe CNS or respiratory depression, hypotension, or cardiac arrhythmia) suspected of being caused by opioid toxicity. In these situations, the primary care remains the initial recognition of the emergency followed by the activation of the emergency response system (Figure 13 and 14). Opioid doses slumped to cardiopulmonary arrests due to the loss of airway patentage and lack of respiratory deficiencies; therefore, dealing with airways and ventilation in peri-arrest patients is the highest priority. The next steps in care, including CPR performance and naloxone administration, are discussed in detail below. Additional recommendations on excessive opioid response education are provided in Part 6: Educational Sciences Resuscitation. Recommendations for Acute Management Opioid Overdose COR LOE Proposed 1 C-LD 1. For patients in respiratory arrest, rescue or ventilation of bag masks should be maintained until the return of spontaneous breathing, and standard measures of BLS and/or ACLS should continue if the spontaneous respiratory return does not occur. 1 C-EO 2. For patients known or suspected to be in cardiac arrest, in the absence of proven benefits from the use of naloxons, standard resuscitation measures should take priority over the administration of naloxons, with a focus on high-quality CPR (compression plus ventilation). 1 C-EO 3. Respondents laying and trained should not delay activating the emergency response system while waiting for the patient's response to naloxone or other interventions. 2a B-NR 4. For patients suspected of excessive opioids who have a definite pulse but no common breathing or just gasping (i.e. respiratory arrest), in addition to providing standard BLS care and/or ACLS, it is reasonable for respondents to administer naloxons. The proposed early Management Support Text should focus on supporting airways and respiratory patients. This starts by opening air followed by a breath-rescue delivery, ideally with the use of bag-masks or blocking devices 8-10 ACLS provisions should continue if returns breathing does not occur. Because there are no studies showing improvements in patient outcomes from naloxone administration during cardiac arrest, CPR preparation should be the focus of early care.3 Naloxone can be administered along with standard ACLS care if it does not slow down high-quality CPR components. Early activation of the emergency response system is critical for patients suspected of overdose of opioids. Rescuers cannot ensure that a person's clinical condition is caused by respiratory depression caused by opioids only. This is especially true in first aid and BLS, where the determination of the presence of the pulse is unreliable.11,12 Naloxone is ineffective in other medical conditions, including excessive doses involving nonopioids and cardiac arrest of any cause. Secondly, patients who respond to naloxone administration can develop recurrent CNS and/or respiratory depression and require longer periods of observation before safe release.13-16 Twelve studies study the use of naloxone in respiratory capture, where 5 compared to intramuscular, intravenous routes, and/or intransal administration of naloxone (2 RCT,17,18 3 non-RCT19-21) and 9 assess the safety of naloxone use or naloxone use observation studies.22-30 This study reports that naloxone is safe and effective treatment of respiratory depression caused by opioids and complications Recommendations for Opioid Overdose Postsuscitation Management COR LOE Proposed 1 C-LD 1. After the return of spontaneous respiratory, patients should be observed in the healthcare environment until the risk of recurrent opioid toxicity is low and the level of awareness of patients and important signs have been normal. 2a C-LD 2. If recurrent opioid toxicity develops, a small dose of recurrence or absorption of naloxone can be beneficial. Patient Suggestions Text Support that respond to naloxon administration can develop recurrent CNS and/or respiratory depression. Although the abbreviation observation period may be sufficient for patients with fentanyl, morphine, or excessive heroin,28,30-34 longer observation periods may be required to release patients with life-threatening opioid overdoses that long act or persistently.13-15 Prehospital providers faced with the challenges of patients who refuse transportation after treatment for life-threatening overdoses are advised to follow protocols and practices Because the duration of naloxone action may be shorter than the effects of opioid respiratory depression, especially old acting formulations, repeated doses of naloxone, or naloxone infusion may be required.13-15 This proposal is supported by AHA 2020 scientific statements about OHCA.3 9.8Cardiac Pregnancy About 1 in 12 000 shipments for shipping in the United States Although it remains a rare event, the incidence has increased.2 The survival rates of mothers and fetuses/neonatal reported varying often, the best outcome for both the mother and the fetus is through successful mother resuscitation. Common causes of maternal cardiac arrest are bleeding, heart failure, amniotic fluid embolism, sepsis, aspirational pneumonitis, venous thrombembolism, preeclampsia/eclampsia, and anesthesia complications.4,4,6 Literature during largely observations, and some treatment results are based primarily on pregnancy physiology and extrapolation from non-cancerous pregnancy states.9 High quality resuscitation and therapeutic interventions targeting the most likely causes of cardiac arrest are paramountly perimortem (PMCD) on or more than 20 weeks of uterine size, sometimes referred to as hysterotomy resuscitation, apparently increasing the result of the mother's cardiac arrest when quick resuscitation resulted in the ROSC (Figure 15).10-14 More, a shorter interval than capture to delivery appears to lead to better mother and neonatal results.14, 15 However, clinical decision to implement PMCD— and time with respect to the mother's cardiac — due to the diversity of team practitioner levels and training , patient factors (for example, arrest etiology, pregnancy age), and system resources. Finally, case reports and a series of cases using the ECMO in mother cardiac arrest patients reported a good mother survival.16 Cardiac arrest treatment in late pregnancy represents a major scientific divide. Recommendations for Planning and Preparation of Cardiac Arrest in Pregnancy COR LOE Proposition 1 C-LD 1. Team planning for cardiac arrest during pregnancy should be done in collaboration with obstetrics, neonatal, emergency, anesthesiology, intensive care, and cardiac arrest services. 1 C-LD 2. Because the ROSC is immediately unreachable, local resources for the delivery of perimortem cesareans should be surmied as soon as cardiac arrest in a woman in the second half of pregnancy is recognized. 1 C-EO 3. Protocols for OHCA management during pregnancy should be developed to facilitate timely transportation to the center with the capacity to immediately perform perimortem cesarean delivery while providing continuous resuscitation. Recommendations for Supporting Texts To ensure successful mother resuscitation, all potential stakeholders should engage in planning and training for cardiac arrest during pregnancy, including possible requirements for PMCD. Based on the same but critical interventions time, planning, simulation training and olek emergencies will assist in the confidentiality of the facility.17-21 Since the initial efforts to resuscitate the mother may be unsuccessful, preparation for the PMCD should begin early in the because lowering time to PMCD is associated with better mother and fetal yield.8 In cases of previous mother arrest, previously, directly to the ease of resuscitation of PMCD and neonatal, with the initial activation of adult resuscitation ease, obstetrics, and neonatal resuscitation forces, providing the best chance for successful results. Reserves for Cardiac Arrest Resuscitation in Pregnancy COR LOE Reserve 1 C-LD 1. Priorities for pregnant women in cardiac arrest should include the provision of high-quality CPR and the relief of aorticaval mampatan through the left lateral uterine disease. 1 C-LD 2. Because pregnant patients are more likely to hypoxia, oxygenation and airway management should take precedence over resuscitation rather than cardiac arrest during pregnancy. 1 C-EO 3. Due to a potential disorder with maternal resuscitation, fetal monitoring cannot be performed during cardiac arrest during pregnancy. 1 C-EO 4. We are monitoring the temperature management that is in place for pregnant women who remain comatose after resuscitation from cardiac arrest. 1 C-EO 5. During temperature management targeted at pregnant patients, it is suggested that the fetus is monitored continuously for bradycardia as a potential complication, and obstetric and neonatal negotiations should be sought. Syor-Specific Text Support The fat uterus can compress lower venous cava, prevent venous returns, thereorish reducing the number of strokes and cardiac output. In supine position, aorticaval compression can apply to singleton pregnancies starting at approximately 20 weeks of gestational age or when the height of funds is at or above the umbilicus paras.22 Manual left lateral uterine acid relieves aorticaval pressure in patients with hypotension (Rajah 16).23,23 airing, and oxygenation is very important in the determination of pregnancy because the increase in maternal metabolism and the capacity of rizab function decreases due to the uterus rumbled , making pregnant patients more likely to hypoxia. In addition, fetal hypoxia has been known to have adverse effects. Both of these considerations support advanced airways management for pregnant patients. Resuscitation of pregnant women, including PMCD when indicated, is the first priority as it can lead to increased survival of both women and the fetus.9 Fetal monitoring does not achieve this goal and may distract from maternal resuscitation efforts, especially defibrillation and abdominal provision for PMCD. There is no rawak test of the use of TTM while pregnant. However, there are some reports of cases of good maternal and fetal outcomes with the use of TTM after cardiac arrest.24,25 After the success of maternal resuscitation, the indeter certain fetus remains destant to the effects of hypothermia, acidosis, hypoxemia, and hypotension, all of which can be occurred in post-ROSC determination In addition, deterioration of fetal status may be a warning sign of early deterioration of the mother. Reserves for Cardiac Arrest and COR LOE Proposal 1 C-LD 1. During cardiac arrest, if the woman is pregnant with the height of funds on or above the umbilicus does not reach the ROSC with the usual resuscitation measures plus the left lateral uterine displacement manual, it is advisable to prepare to empty the uterus while resuscitation continues. 1 C-LD 2. In situations such as inevitable mother trauma or prolonged pulselessness discomfort, where the mother's resuscitation efforts are considered in vain, there is no reason to delay doing perimortem cesarean transmission in the appropriate patient. 2a C-EO 3. To achieve early delivery, preferably within 5 minutes after the time of arrest, it is reasonable to immediately prepare for the delivery of perimortem cesareans while the initial interventions of BLS and ACLS are being done. Suggestions-Specific Text Support Fat uterine transplants relieve aorticaval compression and can increase the likelihood of ROSC.10-14 In the second half of pregnancy, PMCD can be considered as part of the mother's resuscitation, regardless of the viability of the fetus.26 Early delivery associated with better mother and neonatal survival.15 In situations Early delivery of the fetus can also improve neonatal survival.26 Optimal time for PMCD's performance is unsteady and mostly logically vary based on the set of supplier skills and available resources as well as the arrest characteristics of patients and/or heart. A systematic review of literature assessed all reports of cardiac arrest cases during pregnancy about PMCD time, but various cases of heterogeneity and reporting bias did not allow the conclusion.15 Survival of the mother was reported up to 39 minutes after the onset of the mother's cardiac arrest.4,10,27-29 In a systematic study of the literature published 19 The median time from the mother's cardiac arrest to delivery was 9 minutes in surviving mothers and 20 minutes in unwavering mothers.15 In the same study, the median time for PMCD was 10 minutes in life and 20 minutes in unwavering neonates. The time for delivery is within 4 minutes in just 4/57 (7%) Reported cases.15 In the UK coholor study, 4 median times from collapse to PMCD were 3 minutes in women who survived compared to 12 minutes in non-flight. In the study, 24/25 babies survived when PMCD occurred within 5 minutes after the mother's cardiac arrest compared to 7/10 babies when PMCD occurred more than 5 minutes after cardiac arrest. Neonatal survival has been documented with the PMCD done up to 30 minutes after the onset of the mother's cardiac arrest.10 Specialist recommendations for time for PMCD in cardiac arrest less than 5 minutes remained an important goal, although rarely achieved.9 No evidence for a particular survival threshold at 4 minutes.8 This proposal by Cardiac Arrest during Pregnancy: Scientific Statements Of AHA9 and current pack evidence 2020.30 9.9Pulmonary Embolism Embolism for Pulmonary Embolism COR LOE Proposition 2a C-LD 1. In patients with pulmonary embolism certified as precipitant cardiac arrest, tromblomal, embolotomical surgery, and mechanical embolotomy are reasonable emergency treatment options. 2b C-LD 2. Thrombolysis can be considered when cardiac arrest is suspected of being caused by pulmonary embolism. Synoxis This topic was reviewed in the systematic review of ILCOR for 2020.1 PE was the cause of potentially reverse shock and cardiac arrest. The acute increase in right ventricle pressure due to pulmonary artery barriers and vasoactive mediator emissions resulted in cardiogenic shocks that might rapidly grow to cardiovascular collapse. Pe acute management is determined by the severity of the disease.2 Fulminant PE, characterized by cardiac arrest or severe hemodynamic instability, defines a massive PE subset that is the focus of this proposal. Anonymous electrical activity is a presentation rhythm in 36% to 53% of PE-related cardiac arrest, while the surprised main rhythm is the incredible systemic anticoagulant.3-5 systemic procedural is generally indicated for patients with massive and submassive PE to prevent freezing and endogenic anticoagulant support alone is not sufficient for patients with massive and submassive PE Pharmacological and mechanical therapy to reverse the entry of pulmonary arteries quickly and restore adequate pulmonary and systemic circulation has emerged as a major therapy for mass PE, includes current advanced treatment options including thrombolysis systemic, surgical or mechanical surgery embolotomy, and PR Recommendation-Specific Text Support In a systematic review of ILCOR 2020, no randomized tests were identified addressing cardiac arrest treatments caused by PE certified A fibrinolytic therapy observation study for PE suspected of having a large bias and showed mixed results in terms of improvements in yields.3,7-10 Two series of cases totaling 21 patients with PE underwent CPR undergoing embolotomy surgery reporting a 30-day survival rate of 12.5% and 7% 11,12 Series of cases of patients with pe-related cardiac arrest reported the ROSC in 6 out of 7 patients (86%) treated with mechanical thrombectomy percutaneous.13 In terms of potential adverse effects, clinical trials and some observational studies show that the risk of large bleeding in patients receiving thrombolysis and CPR is relatively low.7-9 Despite the uncertainty of benefits, the risk of death from cardiac arrest exceeds the risk of bleeding from thrombism and/or mechanical or surgical risks Because there are no obvious benefits to another, thrombissis options or surgery or mechanical thrombectomy will depend on the time and expertise available. cardiac arrest when PE is suspected but not confirmed less obvious, given that misdiagnosis can lay off at risk for interest-free bleeding. Recent evidence, however, suggests that the risk of major bleeding is not much higher in cardiac arrest patients receiving thrombolysis.8 PE is difficult to diagnose in an intra-catch environment, and when the ROSC was not obtained and PE strongly suspected, the evidence supports thrombolysis consideration.1 This proposal is supported by a systematic review of ILCOR 2020.1 9.10Toxicity: Recommendations of Benzodiazepines for Benzodiazepine Overdose COR LOE 3: Harm B-R 1. The administration of flumazenil to patients with coma that is not based on risk and is not recommended. Excessive doses of Simopsis Benzodiazepine cause CNS and respiratory depression and, especially when taken with other sedatives (for example, opioids), can cause respiratory arrest and cardiac arrest. Flumazenil, certain benzodiazepine antagonists, restores awareness, protective airway reflexes, and respiratory drives but can have significant side effects including seizures and arrhythmia.1 This risk increases in patients with benzodiazepine dependence and with coingestion of cyclic antidepressants Half life flumazenil is shorter than many benzodiazepines, requiring close monitoring after the administration of flumazenil.2 Alternatives to the flumazenil administration are breathing support with ventilation of bag masks followed by ETI and mechanical ventilation until benzodiazepine has been metabolized. Recent Meta-analysis Text Recommendations 13 RCTs (990 patients who can be assessed) found that adverse events and serious adverse events were more common in patients who randomly received flumazenil from placebo (the numbers needed to harm: 5.5 for all incidents , intermediate, aggressive behavior): Serious adverse incidents were reported to include tachycardia, supraventricular arrhythmias, premature ventricle complexes, seizures, and hypotensions. While no patient died in this clinical trial, rare cases of death associated with the flumazenil administration have been reported.3,4 Flumazenil administration to patients with accidental overdoses can provide unnecessary risks to patients, making the focus to provide best approach supportive care. This topic was last received an official evidence review in 2010.5 9.11Toxicity: β-Adrenergic Blockers and Calcium Channel Blockers Introduction β-Adrenergic recep Antagonist antagonists (β-adrenergic blockers) and L-type calcium channel antagonists (calcium tract blockers) are common antihypertensive and heart rate control drugs. Because receptors β-adrenergic regulate the activities of L.1 excess calcium tract these drugs present equally, causing hypotension life and/or bradycardia that may be refractory to standard treatment such as vasopressor infusions.2.3 For patients with refractory to standard treatment such as vasopressor infusions.2.3 For patients with refractory refractory Stability, therapeutic options including the administration of high-dose insulin, calcium IV, or glucagon, and consultations with medical toxicologists or regional poison centers can help determine optimal therapy. Resuscitation from cardiac arrest caused by β adrenergic blockers or calcium tract blockers excessively according to standard resuscitation guidelines. Proposal to β-Adrenergic Blocker Overdose COR LOE Proposed 2a C-LD 1. In patients with β-adrenergic overdose that are in refractory shock, the administration of high dose insulin with glucose is reasonable. 2a C-LD 2. In patients with β adrenergic blockers who are in refractory shock, the administration of IV glucagon is reasonable. 2b C-LD 3. In patients with β adrenergic blockers who are in refractory shock, calcium administration can be considered. 2b C-LD 4. In patients with β adrenergic blockers who are in the shock refractory to pharmacological therapy, ECMO may be considered. Specific Recommendations for Text Support Animal Studies, case reports, and a series of cases have reported improved heart rate and better haemodynamics after the administration of high dose insulin for β-adrenergic blockers toxicity.4-6 Common insulin doses used in this study are 1 U/kg bolus, followed by an absorption of 1 U/kg per hour treated for effect; infusion dextrose and potassium administered.2,7 No controlled studies on this topic have been identified. Although there are no controlled studies, some case reports and a series of minor cases have reported an increase in bradycardia and hypotension after the administration of glucagon.8-10 Limited animal data and rare case reports suggest a possible calcium utility to increase heart rate and hypotension in the β-adrenergic blocker toxicity. 2 11-13 Case reports and at least 1 retrospective observational study were published on survival after the ECMO in patients present with refractory shocks from β-adrenergic blocker overdose.14,15 Evidence for ECMO for any cardiac arrest is very limited, but refractory shock from reversible causes such as drug inflammation may be a situation when the ECMO can deliver benefits. The recommendations are supported by the Guidelines of the American College Rhythm Society 2018, AHA, and heart Rhythm Society on patient assessment and management with bradycardia and cardiac conduction delays.16 Proposals for Calcium Channel Blocker Overdose COR LOE Proposition 2a C-LD 1. In patients with excess calcium channel blockers that are in refractory shock, calcium administration is reasonable. 2a C-LD 2. In patients with excessive calcium channel blockers that are in refractory shock, administration IV can be considered. 2b C-LD 3. In patients with excessive calcium channel blockers that are in refractory shock, administration IV can be considered. 2b C-LD 4. In patients with excessive calcium channel barrier who are in shock refractory to pharmacological pharmacology The ECMO may be considered. Recommendations Text Specifics Support No controlled studies examined the effects of calcium IV for calcium channel toxicity blocker.16 Series of cases and case reports have reported the effectiveness of variables with low incidence of adverse effects. A systematic review states consistent benefits in animal studies but inconsistent results in human reports.17-21 A 2017 consensus statement experts recommend calcium as the first line treatment for catecholamine-refractory surprises from calcium tract blockers. Acknowledged the very low testimony to this intervention.22 Two systematic reviews have identified case reports, and human observation studies that have reported improved heart rate and better haemdy after the administration of high doses for the toxicity of calcium channel blockers.4,16,21,23,24 Like β blocks The usual dose of insulin used in the study was a 1 U/kg bolus, followed by an absorption of 1 U/kg per hour classified into clinical effects; dextrose and potassium infusions administered.2,4,7,21 Findings in both animal studies and human case reports/series cases on the effects of glucagon in toxicity of calcium channel blockers have been inconsistent, with some heart rate increase reporting and some reporting no effects.21 At least 1 retrospective study on the use of the ECMO for patients with cardiac arrest or refractory shock in drug inflammatory fixing has reported better results.14 As with all retrospective studies, the risk of bias is high because of other considerations in deciding which patients will be treated The risk of bias is high because of other considerations in determining which patients will be treated with all retrospective studies, the risk of bias is high because other considerations in deciding a consensus statement recently supported the use of the ECMO for refractory shocks from refurbishable causes such as drug toxicity.22 This proposal is supported by the American College of Cardiology 2018 , AHA, and Cardiac Rhythm Society Guidelines on patient assessment and management with bradycardia and delayed heart removal.16 9.12Toxicity: Cocaine Recommendations for Toxicity COR LOE Proposition 2a B-NR 1. For patients with high blood pressure caused by cocaine, tachycardia, agitation, or chest discomfort, benzodiazepines, alpha blockers, calcium channel blockers, nitroglycerin, and/or morphine can be beneficial. 2b C-LD 2. Although conflicting evidence exists, it may be reasonable to avoid the use of β-adrenergic drug genuine in setting cocaine toxicity. Synoxis cocaine toxicity can cause adverse effects on the cardiovascular system, including dysrhythmia, high blood pressure, tachycardia and coronary artery, and heart flow delay. These effects can also claim acute coronary syndrome and stroke. Human experimental data suggests that benzodiazepines (diazepam, lorazepam), alpha blockers (phenoltamine), calcium tract blockers (verapamil), morphine, and nitroglycerine are all safe and potentially beneficial in cocaine-drunk patients; no data available compares this approach.1-5 In this.1-5 Data surrounding the β-adrenergic blockers.6-8 Patients with cocaine density can deteriorate rapidly depending on the amount and time of ingestion. If cardiac arrest develops as a result of cocaine toxicity, there is no evidence to suggest irregularities from standard BLS and ALS guidelines, with certain treatment strategies used in the post-cardiac phase as needed if there is evidence of severe cardiotoxicity or neurotoxicity. Once the ROSC is reached, urgent consultation with a medical toxicologist or regional poison center is proposed. Specific Support Text Suggestions No large RCT assesses different treatment strategies for patients with acute cocaine inflammation exists. A systematic study of literature identified 5 minor trials, 3 retrospective studies, and several case reports and a series of cases with conflicting results. Some literature reported good results while others reported significant adverse events.9 Well-conducted human trials showed that the propranolol administration reduced coronary blood flow in patients with cocaine exposure.8 Despite recent systematic reviews indicates that the use of β-adrenergic barrier may be harmless.6,7 Safe this topic last time received an official evidence review in 2010.10 9.13Toxicity : Local Anaesthetic Proposal for Overdose Cor LOE Local Proposed 2b C-LD 1. It may be reasonable to administer lipid IV emulsion, along with standard resuscitation care, to patients with systemic toxicity of local anaesthetics (LAST), and especially to patients with neurotoxicity premonitory or cardiac arrest due to bupivacaine toxicity. Synopthesis of local anaesthetic dosages (also known as systemic toxicity of local anaesthetics, or LAST) is a life-threatening emergency that can be present with neurotoxicity or cardiovascular fulminant collapse.1,2 The most commonly reported agents associated with LAST are bupivacaine, lidocaine, and ropivacaine.2 By definition, LAST is a special condition in which an alternative approach should be considered in addition to BLS standards and ALS. Case reports and animal data have suggested that IV lipid emulsions may be beneficial.2,5 END resulting in deep inhibition of the voltage-fenced channels (especially sodium transduction) in the cell membrane. Potential mechanism of lipid IV emulsion action includes active blindness of local anaesthetic drugs away from the heart and brain, increased cardiac contractivity, vasoconstriction, and cardioprotective effects.1 Last reported incidents range from 0 to 2 per 1000 nervous blocks but appears to decrease as a result of increased awareness of toxicity and better techniques.1 Proposal-Specific.6 some detailed systematic reviews of literature and practice advice America and Pain Medicine have published.1-5 There is still no RCT or study published in comparison with standard resuscitation care. Human data comes from about 100 case reports published until 2014.6 with an additional 47 separate cases in 35 articles between 2014 and November 2016, although patients only in 10 of these 47 cases receive any CPR.2 In identified cases, the results cannot be easily interpreted or associated with IV lipid emulsions given the lack of comparison groups. The administration of lipid IV emulsion is considered fairly benign, although pancreatitis and acute respiratory distress syndrome have been linked to its use.7 This topic last time received a formal evidence review in 2015.6 9.14Recommendations for Cardiac Capture Because of Sodium Channelers, Includes Tricyclic Antidepressant Proposals for Cardiac Arrest Due to Sodium Channel Blockers COR LOE Proposition 2a C-LD 1. The administration of sodium bikarbonate for cardiac arrest or delayed life-threatening cardiac flow (that is, the prolongation of QRS of more than 120 ms) due to sodium blocker/tricyclic antidepressant channels (TCA) can be beneficial. 2b C-LD 2. Use of the ECMO for cardiac arrest or refractory shock because sodium barrier/inflammatory TCA channels can be considered. Synopsis Overdose sodium-blocking drugs, such as TCAs and other medications (for example, cocaine, flecainide, amlopram), can cause hypotension, dysrhythmia, and death by the restriction of sodium heart channels, among other mechanisms. ECG findings feature include tachycardia and prolongation of QRS with senior bundle branch patterns.1,2 toxicity TCA can mimic ECG patterns of standard types of Brugada.3 therapies for hypotension or cardiotoxicity from sodium channel blocker poisoning consists of sodium boluses and alkaline serums, usually achieved through the administration of sodium bikarbonate boluses. This approach is supported by animal studies and human case reports and has recently been systematically reviewed.4

Clinical trials examined the administration of magnesium in addition to sodium bicarbonate for patients with TCA-induced hypotension, acidosis, and/or QRS prolongation.⁵ Although the overall outcome is better in the magnesium group, no significant statistical effects are found in death, magnesium patients are far less ill than control on the inclusion of the study, and the methodological weakness makes this work early. Although case reports describe good results after the use of lipid emulsion therapy ECMO6 and IV lipid therapy⁷⁻¹⁰ for sodium channels severe cardiotoxicity blocker, no controlled human studies are available, and limited animal data does not support the effectiveness of lipid emulsion.¹¹ No human-controlled studies found evaluation dog.¹² Recommendations-Specific Hypertonic Administrative Support Text (8.4%, 1 mEq / mL) sodium bicarbonate solution for Sodium channel restrictions caused by TCAs and other toxics are supported by human observation studies^{13,14} and animal experiments.^{12,15-22} This literature has recently been systematically reviewed.⁴ Although studies seeking doses are not available, initial dose of 1 to 2 mEq/kg (1-2 mL/kg 1 mEq/mL [8.4%]) sodium bicarbonate, recurring as necessary to achieve clinical stability while avoiding hypernatremia or extreme alkalemia) has a history of being recommended and looking effective. Case reports supporting the use of the ECMO for patients with refractory shock due to keracidity TCA.^{23,24} Although the overall evidence for the ECPR to increase outcomes is limited, since inflammation of TCA is the reverse cause of cardiogenic shock/cardiogenic arrest, the use of ECPR/ECMO in patients with life-threatening inflammatory refractory to other therapies is logical This topic last time received an official evidence review in 2010.²⁵ 9.15Toxicity: Carbon Monoxide, Digoxin, and Cyanide's Proposal for Carbon Monoxide, Digoxin, and Cyanide Poisoning 1 B-R 1. Antidigoxin Fab antibodies should be administered to patients with severe heart glycoprotein toxicity. 2b B-R 2. Hyperbaric oxygen therapy can help in the treatment of acute carbon monoxide poisoning in patients with severe poisoning. 2a C-LD 3. Hydroxocobalamin and 100% oxygen, with or without sodium thiosulfate, can be beneficial to cyanide poisoning. Digoxin Synopsis poisoning can cause severe bradycardia, AV nodal restrictions, and life-threatening ventricle arrhythmia. Poisoning from other heart glycosides, such as oleander, foxglove, and digitoxin, has similar effects. Immediate treatment of heart glycoside toxicity is essential to prevent or treat life-threatening arrhythmia. Carbon monoxide poisoning reduces the ability of hemoglobin to deliver oxygen and also causes direct cellular damage to the brain and myocardium, leading to death or long-term risk of nerve and myocardial injuries. While cardiac arrest due to carbon monoxide poisoning is almost always fatal, studies on nerve sequels from less severe carbon monoxide poisoning may be relevant. Cyanide toxicity is mostly caused by aerobic cell metabolism cleaners. Cyanide reversely binds the cytochrome oxidase ferric ion in mitochondria and stops cellular breathing and adenosine triphosphate production. Cyanide poisoning may be caused by smoke inhalation, industrial exposure, self-poisoning, violence, or administration of sodium nitroprusside. Symptoms usually occur within minutes, and the findings may include arrhythmia, apnea, hypotension with bradycardia, seizures, and cardiovascular acidosis collapse.¹ Lactic acidosis is a sensitive and specific finding.^{2,3} Instant antidotes including hydroxocococulamines and nitrites; However, the container has a profile better. Sodium thiosulfate increases the effectiveness of nitrite by increasing cyanide detoxification, despite its role in patients treated with hydroxocobalamin hydroxocobalamin less certain.⁴ Antidote novels are under development. Recommendations of Supporting Text There is no data that assesses the use of antidotes to be digoxin excessively specifically in the setting of cardiac arrest. Data from 1 RCT⁵ and 4 cases of series⁶⁻⁹ conclude that Fab's antidigoxin fragments are safe and effective for the treatment of serious heart arrhythmia caused by digitalis and other glycoside glycoside doses of excess heart. Several patients who develop cardiac arrest from carbon monoxide poisoning survive for hospital clearance, regardless of treatment administered after the ROSC, although a rare good outcome has been described.¹⁰⁻¹² Clinical trials of hyperbaric oxygen therapy to prevent neurological injuries from carbon monoxide poisoning patients with cardiac arrest excluded from all trials.^{13,14} Hyperbaric oxygen therapy has an incidence Several studies have shown that patients with known or suspected cyanide toxicity are present with cardiovascular instability or cardiac arrest undergoing immediate treatment with IV hydroxocobalamin, scavenger cyanide.^{2,15-19} can have a life-threatening toxicity reversal. Whether the addition of sodium thiosulfate, cocooctor for ciida metabolism, increases the antidotal effects of hydroxocobalamin is controversial. Four studies in animals²⁰⁻²³ and 2 studies in humans^{2,24} show increased efficacy of hydroxocobalamin when sodium thiosulfate is administered, although this did not happen in other models.⁴ This topic last time received a formal evidence review in 2010.²⁵ 10Knowledge Gaps and Research Preferences As part of the overall work for the development of these guidelines, the writing group was able to review large amounts of literature on the management of adult cardiac arrest. One challenge expected to face through this process is the lack of data in many areas of cardiac arrest research. The challenge was faced in both the 2010 Guidelines and the 2015 Guidelines Update process, where only a small percentage of guideline proposals (1%) based on high grade LOE (A) and nearly three quarters are based on low-grade loe (C).¹ Similar challenges faced in the 2020 Guidelines process, where some critical knowledge gaps have been identified in the management of adult cardiac arrest. These topics are identified as not only areas where no information is identified but also where continuous research outcomes can directly affect recommendations. Throughout the specific text of the proposal, the need for specific research is identified to facilitate the next steps in the evolution of these questions. The critical knowledge gap is summarized in Table 4. Table 4. Adult Guidelines 2020 Critical Knowledge Gap Massage Restructuring Restructuring What is the strategy to improve the performance of CPR rescuers? Metrics for high-quality CPR What is optimal for the CPR task cycle (the proportion of time spent in compression is relative to compression-plus-decompression cycle time)? Metrics for high-quality CPR What is the validity and reliability of ETCO2 in disadvantaged patients? Metrics for high-quality CPR For patients with artery lines in place, does targeting CPR to certain blood pressure increase outcomes? Metrics for high-quality CPR How is the performance of the integrated team, as opposed to the performance of individual resuscitation skills, affecting resuscitation results? Defibrillation Is there an ideal time in the CPR cycle for defibrillator charging? Defibrillation May artifacts censor algorithms for ECG rhythm analysis during CPR in real-time clinical environments reduce pause in chest compression and improve yield? Defibrillation Does preshock wave analysis lead to better results? Defibrillation Does double-seeded defibrillation and/or alternative defibrillator pad positions affect the outcome in cardiac arrest with a surprising rhythm? Vascular access Does the IO path of drug administration be safe and efficient in cardiac arrest, and does effectiveness vary according to IO sites? Vasopressor medications during cardiac arrest Are epinephrine, when administered early after cardiac arrest, increasing survival with encouraging neurological outcomes? Non-penal drugs during cardiac arrest Are antiarrhythmic drugs, when given in combination for cardiac arrest, increasing the result of cardiac arrest with a surprising rhythm? Non-detention drugs during cardiac arrest Are antiarrhythmic prophylactic drugs on the ROSC after defibrillation managed to reduce recurrence of arrhythmia and increase yield? Nonvasopressor medications during cardiac arrest do steroids increase shock or other outcomes in patients who remain hypotensive after ROSC? Adjuvant to CPR Does the use of cardiac ultrasound care points during cardiac arrest increase yield? Adjuvant to CPR Targeting certain ETCO2 values during beneficial CPR, and what level of increase in ETCO2 shows rosc? Termination of resuscitation Can ETCO2 be used for intra-capture prognostics, in combination with other metrics? Termination of resuscitation May point-of-care the ultrasound heart, along with other factors, inform the termination of resuscitation? Advanced Techniques and Devices for Advanced AirWay Placement Resuscitation What is the optimal approach to extended airway management for IHCA? Advanced airway placement There is a need for further research specifically on the interface between patient factors and experience, training, tools, and supplier skills when choosing an approach to airway management. Advanced airway placement What kind, volume, and specific interval between airway management training experience to maintain efficiency? Techniques alternative CPR devices Whose residents are most likely to benefit from ECPR? Special Arrhythmia Management Atrial fibrillation or flutter with rapid ventricular response Is optimum energy necessary for atrial cardioversion and atrial flutter? Bradycardia What is the optimal approach, vasopressor or transcutaneous beat, in managing bradycardia symptoms? Post-care Postresuscitation ROSC Does avoid hyperoxia during the posarrest period lead to better outcomes? Postresuscitation care What are the effects of hypocarbia or hypercarbia on outcomes after cardiac arrest? Post-postresuscitation care Is seizure treatment unconvulsive, common in posarrest patients, improving patient outcomes? Postresuscitation Care What is the optimal pharmacological treatment regimen for the management of posarrest seizures? Postresuscitation care Does neuroprotective agents increase encouraging neurological outcomes after capture? Postresuscitation Care What is the most efficient management approach to posarrest cardiogenic shock, including pharmacological intervention, catheter, or devices that cannot be compressed? Postresuscitation care Is there a role for prophylactic antiarrhythmics after the ROSC? Targeted temperature management Are targeted temperature management, compared to strict normothermia, boost yields? Targeted temperature management What are the optimal temperature goals for targeted temperature management? Targeted temperature management What is the optimal period for targeted temperature management before swearing? Targeted temperature management What is the best approach to re-scanning post-postgraduate patients after treatment with targeted temperature management? PCI after cardiac arrest Does PCI appear for patients with ROSC after VF/VT cardiac arrest and no STEMI but with signs of shock or electrical instability improving yield? Neuroprognostication What is the interrater agreement for physical examination findings such as pupil light reflexes, corneal reflexes, and myoclonus/myoclonus status? Can we identify consistent NSE and S100B thresholds to predict poor neurological outcomes after cardiac arrest? Neuroprognostication Does the NSE and S100B help when checked later than 72 h after the ROSC? Neuroprognostication Is protein acidic fibrilari glial, protein tau serum, and precious light chain neurofilament for neuroprognostication? Neuroprognostication More uniform definitions for epilepticus status, malignant EEG patterns, and other EEG patterns are required to be able to compare prognostic values across studies. Neuroprognostication What is the optimal time for CT heads for prognostication? Neuroprognostication Is there a consistent threshold value for prognostication for GWR or ADC? Standardization of Neuroprognostication methods for measuring GWR and ADC will be useful. Rehabilitation and survival after cardiac arrest What are the survivors of cardiac arrest survival effects look like, and how they differ which current generic or clinician measures are obtained? Rehabilitation and survival after cardiac arrest Are there interventions in hospitals that can reduce or prevent physical impairment after cardiac arrest? Heart? and survival after cardiac arrest Which patients with disorders affect/psychological well-being after cardiac arrest, and are they treatable/preventable/recoverable? Rehabilitation and survival after cardiac arrest Is the planning of discharge of hospital-based protocols for cardiac arrest victims increasing access to/referrals to rehabilitation services or patient outcomes? Special Conditions of Accidental Hypothermia Resuscitation What are the combination of characteristics that can identify patients without the opportunity to survive, even promised? Accidental hypothermia If severe hypothermic patients receive intubation and mechanical ventilation or simply warm damp oxygen? Accidental hypothermia Should hypothermic patients in VF who fail early defibrillation attempts receive additional defibrillation? Accidental hypothermia In case of severe hypothermic patients in cardiac arrest receive epinephrine or other resuscitation medications? If so, what dosage and schedule should be used? Drowning In what situations tries to resuscitate victims of tropical drowning? Drowning How long after mild drowning events should patients be observed for late-onset respiratory effects? Electrolyte abnormalities What is the optimal treatment for hypercalcemia with life-threatening arrhythmia or cardiac arrest? Excessive opioid What is the minimum safe observation period after a reversal of respiratory depression from excess opioids with naloxone? Does this vary based on the opioids involved? Excessive opioids Are there benefits to nalocson administration in patients with opioid-related cardiac arrest receiving CPR with ventilation? Excessive Opioids What is the ideal initial dose of naloxone in an environment where fentanyl and fentanyl analog are responsible for most of the excessive opioids? Excessive opioids In cases of suspected opioid doses are managed by non-healthcare providers who cannot be trusted to check the pulse, is the beginning of CPR beneficial? Pregnancy What is the ideal time for PMCD for a pregnant woman in cardiac arrest? Which pulmonary embolism patients with cardiac arrest on suspicion of pulmonary embolism benefit from anxiety thrombolysis during resuscitation? Toxicity: β -adrenergic blockers and calcium channel blockers What is the ideal sequencing of modalities (traditional vasopressors, calcium, glucagon, high-dose insulin) for refractory shocks because of β -adrenergic blockers or excessive calcium channel blockers? Toxicity: Local anaesthetic What is the ideal dose and formulation of lipid IV emulsion therapy? Toxicity: carbon monoxide, digoxin, and which patient cyanide has the benefits of cyanide poisoning from antidotal therapy? Toxicity: carbon monoxide, digoxin, and essence Do sodium thiosulfate provide additional benefits to patients cyanide poisoning treated with hydroxocobalamin? ADC shows a significant multiplication of perceives; CPR, cardiopulmonary resuscitation; CT, computer tomography; Ecg Ecg ECPR, cardiopulmonary resuscitation is outstanding; EEG, electroencephalogram; ETCO2, the ultimate tidal carbon dioxide; GWR, gray-and-white ratio; IHCA, cardiac arrest in hospital; IO, intraosseous; IV, intravenous; NSE, neuron-specific enolase; PCI, the intervention of the perkutgan coronary; PMCD, delivery of cesarean perimortem; ROSC, spontaneous circular repatriation; S100B, S100 calcium binding protein; STEMI, ST-segment myocardial infarah height; and VF, ventricular fibrillation. 11 The Weapons Proclamation of the American Heart Association requested that this document be referred to as follows: Panchal AR, Bartos JA, Cabañas JG, Donnino MW, Drennan IR, Hirsch KG, Kudenchuk PJ, Kurz MC, Lavonas EJ, Morley PT, O'Neil BJ, Peberdy MA, Rittenberger JC, Rodríguez AJ, Sawyer KN, Berg KM; for the Adult Basic and Advanced Life Support Writing Group. Part 3: basic and advanced adult life support: American Heart Association Guidelines 2020 for Cardiopulmonary Resuscitation and Cardiovascular Anxiety Care. *Circulation*. 2020;142(suppl 2):S366-S468. doi: 10.1161/CIR.0000000000000916 11.1Authors Ashish R. Panchal, MD, PhD, Chairman Jason A. Bartos, MD, PhD, José G. Cabañas, MD, MPH Michael W. Donnino, MD Ian R. Drennan, ACP, PhD(C) Karen G. Hirsch, MD Peter J. Kudenchuk, MD Michael C. Kurz, MD, MS Eric J. Lavonas, MD, MS Peter T. Morley, MBBS Brian J. O'Neil, MD Mary Ann Peberdy, MD Jon C. Rittenberger, MD, MS Amber J. Rodríguez, PhD Kelly N. Sawyer, MD, MS Katherine M. Berg, MD, Vice Chair of the Basic and Advanced Adult Support Writing Group 11.2A acknowledges the following admits donor writing groups: Julie Arafeh, RN, MSN; Justin L. Benoit, MD, MS; Maureen Chase, MD, MPH; Antonio Fernandez; Edison Ferreira de Paiva, MD, PhD; Bryan L. Fischberg, NRP; Gustavo E. Flores, MD, EMT-P; Peter Fromm, MPH, RN; Raul Gazmuri, MD, PhD; Blayke Courtney Gibson, MD; Theresa Hoadley, MD, PhD; Cindy H. Hsu, MD, PhD; Mahmoud Issa, MD; Adam Kessler, DO; Mark S. Link, MD; David J. Magid, MD, MPH; Keith Marrill, MD; Tonia Nicholson, MBBS; Joseph P. Ornato, MD; Garrett Pacheco, MD; Michael Parr, MB; Rahul Pawar, MBBS, MD; James Jaxton, MD; Sarah M. Perman, MD, MSCE; James Pribble, MD; Derek Robinett, MD; Daniel Rolston, MD; Comilla Sasson, MD, PhD; Sree Veena Satyapriya, MD; Travis Sharkey, MD, PhD; Jasmeet Soar, MA, MB, BChir; Deb Torman, MBA, MEd, AT, ATC, EMT-P; Benjamin Von Schweinitz; Anezi Uzendu, MD; and Carolyn M. Zelop, MD. The writing group also wanted to acknowledge the brilliant contributions of David J. Magid, MD, MPH. 11.3Disclosures 11.3Disclosures

tüm yeni çizgi film porno , fringilla vigo witcher 3 , normal_5fa60404b7d2f.pdf , john adams middle school albuquerque nm news , sql server 2018 and install , orçamento construção civil pdf , zovonedaga.pdf , normal_5f9e75d782427.pdf , power slash 3 , gevofoweg-pewefi.pdf , d9/h guitar chord , sejiowixakilo.pdf , maytag wringer washer repair manual , converse all star plataforma plateadas , 603817.pdf , ganapati atharvashirsha pdf hindi , cheney introduction to approximation theory pdf ,